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American Heart Association (AHA) support their mem-
bers’ goal to improve the care of patients with car-
diovascular disease through professional education,
research, and development of guidelines and standards
and by fostering policies that support optimal patient
outcomes. The ACC and AHA recognize the importance of
the use of clinical data standards for patient management,
assessment of outcomes, and conduct of research, and the
importance of deﬁning the processes and outcomes of
clinical care, whether in randomized trials, observational
studies, registries, or quality-improvement initiatives.
Clinical data standards strive to deﬁne and standardize
data relevant to clinical concepts, with the primary goal
of facilitating uniform data collection by providing a
platform of clinical terms with corresponding deﬁnitions
and data elements. Broad agreement on a common
vocabulary with reliable deﬁnitions used by all is vital to
pool and/or compare data across clinical trials to promote
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405interoperability with electronic health records (EHRs) and
to assess the applicability of research to clinical practice.
The ultimate purpose of clinical data standards is to
contribute to the infrastructure necessary to accomplish
the ACC’s mission of fostering optimal cardiovascular care
and disease prevention and the AHA’s mission of building
healthier lives, free of cardiovascular diseases and stroke.
The speciﬁc goals of clinical data standards are:
1. To establish a consistent, interoperable, and universal
clinical vocabulary as a foundation for both clinical
care and clinical research, including clinical trials
2. To promote the ubiquitous use of EHRs and facilitate
the exchange of data across systems through harmo-
nized, standardized deﬁnitions of key data elements
3. To facilitate the further development of clinical regis-
tries, quality- and performance-improvement pro-
grams, outcomes evaluations, and clinical research,
including the comparison of results within and across
these initiatives
The key elements and deﬁnitions are intended to facil-
itate the consistent, accurate, and reproducible capture of
clinical concepts; standardize the terminology used to
describe cardiovascular diseases and procedures; create a
data environment conducive to the assessment of patient
management and outcomes for quality and performance
improvement and clinical and translational research; and
increase opportunities for sharing data across disparate
data sources. The ACC/AHA Task Force on Clinical Data
Standards selects cardiovascular conditions and pro-
cedures that will beneﬁt from creation of a standard
dataset. Subject matter experts are selected to examine/
consider existing standards and develop a comprehensive,
yet not exhaustive, standard dataset. When a data collec-
tion effort is undertaken, only a subset of the elements
contained in a clinical data standards listing may be
needed, or conversely, users may want to consider
whether it may be necessary to collect some elements not
listed. For example, in the setting of a randomized clinical
trial of a new drug, additional information would likely be
required regarding study procedures and drug therapies.
The ACC and AHA recognize that there are other national
efforts to establish clinical data standards, and every
attempt is made to harmonize newly published standards
with existing standards. Writing Committees are instruc-
ted to consider adopting or adapting existing nationally
and internationally recognized data standards if the deﬁ-
nitions and characteristics are useful and applicable to the
set under development. In addition, the ACC and AHA
are committed to continually expanding their portfolio
of data standards andwill create new standards and update
existing standards as needed to maintain their currency
and promote harmonizationwith other standards as health
information technology and clinical practice evolve.The Writing Committee for the current effort was
intentionally expanded to include a regulatory perspec-
tive. This reﬂects the key role of clinical event concepts in
evaluating therapeutic safety and effectiveness in clinical
trials. This unique collaboration between the regulatory
sector and the ACC and AHA acknowledges the need to
align key clinical concepts for regulatory reporting and
clinical care.
The Health Insurance Portability and Accountability
Act privacy regulations, which went into effect in April
2003, have heightened all practitioners’ awareness of our
professional commitment to safeguard our patients’ pri-
vacy. The Health Insurance Portability and Accountability
Act privacy regulations (1) specify which information
elements are considered “protected health information.”
These elements may not be disclosed to third parties
(including registries and research studies) without the
patient’s written permission. Protected health informa-
tion may be included in databases used for healthcare
operations under a data use agreement. Research studies
using protected health information must be reviewed by
an institutional review board or a privacy board.
We have included identifying information in all clinical
data standards to facilitate uniform collection of these
elements when appropriate. For example, a longitudinal
clinic database may contain these elements because ac-
cess is restricted to the patient’s caregivers. Conversely,
registries may not contain protected health information
unless speciﬁc permission is granted by each patient.
These ﬁelds are indicated as protected health information
in the data standards.
In clinical care, caregivers communicate with each
other through a common vocabulary. In an analogous
fashion, the integrity of clinical research depends on ﬁrm
adherence to prespeciﬁed procedures for patient enroll-
ment and follow-up; these procedures are guaranteed
through careful attention to deﬁnitions enumerated in
the study protocol, case report forms, and clinical event
committee charters. When data elements and deﬁnitions
are standardized across studies, comparison, pooled
analysis, and meta-analysis are enabled, thus deepening
our understanding of individual studies.
The recent development of quality-performance mea-
surement initiatives, particularly those for which the
comparison of providers is an implicit or explicit aim, has
further raised awareness about the importance of data
standards. Indeed, a wide audience, including nonmed-
ical professionals such as payers, regulators, and con-
sumers, may draw conclusions about care and outcomes.
To understand and compare care patterns and outcomes,
the data elements that characterize them must be clearly
deﬁned, consistently used, and properly interpreted.
William S. Weintraub, MD, MACC, FAHA
Chair, ACC/AHA Task Force on Clinical Data Standards
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406FOREWORDThis publication, commissioned by the ACC/AHA, is the
product of a novel collaboration between the ACC and
AHA, the US Food and Drug Administration (FDA), and the
Standardized Data Collection for Cardiovascular Trials
Initiative (SCTI). The aim of the collaboration is to pro-
mulgate, for regulatory submissions, clinical data stan-
dards for key cardiovascular and stroke endpoint events
in clinical trials. The Writing Committee for this particular
data standard is unique in that it was convened to achieve
the following goals: to address issues particular to regu-
latory submissions and to provide a framework of data
standards that would simplify the design and conduct of
clinical trials for those considering regulatory sub-
missions. The intent of this Writing Committee is not
to be overly prescriptive. For example, the stroke data
elements are minimal by design to allow for ﬂexibility
needed to conduct global clinical trials for drugs and
devices. In a trial focused on the treatment of stroke,
investigators may deﬁne additional outcomes and data
elements for a particular stroke treatment or indica-
tion. The Writing Committee recognizes that these
standards may be used for other types of clinical trials
and clinical care processes where appropriate. These
data standards are a ﬁrst step in developing a uni-
versal language for clinical trials and other types of
health-related research.1. INTRODUCTIONEffective communication is a cornerstone of the health-
care enterprise. A prerequisite for providing seamless
care is the universal and consistent use of medical
vocabularies (2). Cardiovascular endpoints such as death,
myocardial infarction, stroke, and revascularization are
critical in assessing diagnostic and therapeutic ap-
proaches in the clinical care, research, and regulatory
domains. With the adoption of EHR solutions has come
the opportunity to manage health-related information as
discrete data (3). Therefore, the ACC/AHA Task Force on
Clinical Data Standards established this Writing Commit-
tee to identify and harmonize the common data elements
involved in key cardiovascular endpoint events. Doing so
will allow this vocabulary to be used to improve the
assessment of process, performance, and outcomes across
multiple dimensions of health care.
In this work, the term “vocabulary” includes the ter-
minology concept, the concept deﬁnition, a suggested
label for the corresponding data element, permissible
values of the data element, and deﬁnitions for the
permissible values.
The Writing Committee identiﬁed the ongoing work of
the SCTI as the foundation for the development of thisvocabulary. The Writing Committee’s task was to review,
reﬁne, and advance as a clinical standard the cardiovas-
cular endpoint terminology set developed by the SCTI.
This terminology set largely reﬂects endpoints related to
the symptoms, manifestations, treatment, and conse-
quences of coronary artery disease in both cardiovascular
and noncardiovascular drug and device trials. Endpoint
concepts related to carotid/cerebral revascularization,
peripheral surgical revascularization, and treatment
of diseases of the aorta are beyond the scope of this
document.
First convened in 2009 by the FDA, the SCTI is a
working group formed to improve the quality and ef-
ﬁciency of clinical trials. It includes representatives
from academia, professional societies, the Clinical Data
Interchange Standards Consortium, Health Level 7, the
Clinical Trials Transformation Initiative, pharmaceutical
and cardiovascular device manufacturers, and the FDA
(which includes the Center for Drug Evaluation and
Research and the Center for Devices and Radiological
Health). The original goal of the working group was to
improve the quality and efﬁciency of cardiovascular
clinical trials (e.g., acute coronary syndrome trials,
percutaneous coronary intervention [PCI] trials). Sub-
sequently, in recognition of the growing interest in
cardiovascular events in noncardiovascular trials (e.g.,
diabetes control trials, weight loss trials), this focus
expanded to include noncardiovascular trials. To ach-
ieve its goal, the SCTI acknowledged the need for a
consistent cardiovascular and stroke endpoint vocabu-
lary comprising terms deﬁned by objective criteria
and reported uniformly (4). This framework of stan-
dardized key data elements in clinical trials (and
potentially the clinical care domain), could also facili-
tate the conduct of meta-analyses to assess cardiovas-
cular safety and compare the effectiveness of drug and
device products.
The SCTI-developed working draft “Standardized
Deﬁnitions for Cardiovascular and Stroke Endpoint
Events in Clinical Trials” is the source document for the
data standards in this publication (4). This source docu-
ment identiﬁes the cardiovascular and stroke endpoint
terms relevant to clinical trials and regulatory sub-
missions. The Writing Committee evaluated and harmo-
nized these endpoint terms, categorized the attributes of
each data element, developed permissible (i.e., allowed)
values, and tabulated the content to facilitate computa-
tional interoperability and the use of the terminology
regulatory domains.
The objective is to use this controlled terminology,
initially developed for clinical trials and regulatory
submissions, to standardize event reporting and data
collection when determinations must be made about
cardiovascular and stroke endpoints in the context of
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drug or device surveillance.
Nonetheless, the Writing Committee recognizes that
this terminology is not applicable to all dimensions of
health care and that some of these deﬁnitions are not
applicable to clinical care processes. For example, the
“Hospitalization for Unstable Angina” deﬁnition may not
be optimal for the Centers for Medicare and Medicaid
Services because other clinical scenarios could be
consistent with unstable angina but not fulﬁll all the
criteria needed to deﬁne this endpoint in a clinical trial.
Similar scenarios could be relevant to other nonfatal
endpoint deﬁnitions.
To avoid ambiguity, we recommend maintaining the
cardiovascular and stroke endpoint vocabulary described
in this document as “regulatory speciﬁc” distinct from
other vocabularies. Although endpoint deﬁnitions may
evolve over time, a period in which deﬁnitions remain
static is needed for terms to be used successfully to
conduct a meta-analysis. Furthermore, the ACC/AHA Task
Force on Clinical Data Standards should include regula-
tory data standards experts—in addition to members of
this Writing Committee, SCTI representatives, and other
clinical trial experts—as an integral part of any necessary
deﬁnition revision process, because such experts under-
stand the requirements for evaluating drug and device
products.2. METHODOLOGY2.1. Writing Committee Composition
The ACC/AHA Task Force on Clinical Data Standards
selected the members of the Writing Committee. The
committee consisted of 16 people with domain expertise
in internal medicine, cardiovascular medicine, neurology,
clinical research, epidemiology, invasive and interven-
tional therapies, outcomes assessment, medical infor-
matics, health information management, and healthcare
services research and delivery.
2.2. Relationships With Industry and Other Entities
The ACC/AHA Task Force on Clinical Data Standards
makes every effort to avoid actual or potential conﬂicts of
interest that might arise as a result of an outside rela-
tionship or a personal, professional, or business interest
of any member of the Writing Committee. Speciﬁcally, all
members of the Writing Committee are required to com-
plete and submit a disclosure form showing all such re-
lationships that could be perceived as real or potential
conﬂicts of interest. These statements are reviewed by the
ACC/AHA Task Force on Clinical Data Standards and
updated when changes occur. Authors’ and peer re-
viewers’ relationships with industry and other entities
pertinent to this data standards document are disclosed inAppendixes 1 and 2, respectively. In addition, for com-
plete transparency, the disclosure information of each
Writing Committee member—including relationships
not pertinent to this document—is available as an
online supplement at http://jaccjacc.cardiosource.com/
acc_documents/Comprehesive_RWI_CV_Endpointsv1.pdf.
The work of the Writing Committee was supported
exclusively by the ACC and AHA without commercial
support. Writing Committee members volunteered their
time for this effort. Meetings of the Writing Committee
were conﬁdential and attended only by committee
members and staff.
2.3. Review of Literature and Existing Data Deﬁnitions
Cardiovascular endpoint concepts have long been used in
clinical care and research to ascertain and assess out-
comes of diagnostic and therapeutic approaches. A series
of reference publications provided the foundation for the
cardiovascular endpoint concepts identiﬁed by the SCTI
and developed by the Writing Committee (5–14). What
makes this work unique is that it reviews and reﬁnes the
terms as developed by the SCTI explicitly for use in
reporting clinical trial results and in regulatory sub-
missions, and it delineates where these concepts could or
should not be used as the foundational vocabulary in
routine clinical care.
2.4. Development of Terminology Concepts
The terminology set addressed in this body of work in-
cludes cardiovascular endpoints of universal interest in
clinical care, research, and regulatory review: death
(speciﬁcally attribution of the cause of death), myocardial
infarction, stroke, transient ischemic attack (TIA), coro-
nary intervention (including stent thrombosis), periph-
eral vascular intervention, hospitalization for unstable
angina, and acute heart failure (HF) events.
The Writing Committee aggregated, reviewed, harmo-
nized, and extended these terms to develop a controlled,
semantically interoperable, machine-computable termi-
nology set that would be usable, as appropriate, in
as many contexts as possible. As necessary, the
Writing Committee identiﬁed the contexts where indi-
vidual terms required differentiation depending on their
proposed use (i.e., research/regulatory versus clinical care
contexts).
The Writing Committee tabulated the content and
provided sufﬁcient structure to build and model the
informatics formalisms to achieve computational inter-
operability. The resulting appendices (Appendixes 3–7
and 9–11) list the “terminology concept” in the ﬁrst
column, followed by a clinical deﬁnition (“concept
deﬁnition”) of the terminology concept in the second
column. A data element label is suggested for forms-based
approaches to data capture. The allowed responses
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in the next column are the acceptable “answers” for
capturing the information. For terminology concepts
with multiple permissible values, a bulleted list of the
permissible values is provided in the same row as the
terminology concept, with successive rows listing each
permissible value and corresponding permissible value
deﬁnition. The process of converting the prose descrip-
tion of an endpoint into this tabular format can be seen by
comparing the source text for a HF endpoint event
(Appendix 8, an excerpt from the SCTI draft document)
and the tabular representation of the same concept in
Appendix 7. Where possible, clinical deﬁnitions of end-
points (and the corresponding permissible values) are
repeated verbatim as deﬁned by the SCTI or as previously
published in reference documents.
2.5. Consensus Development
The ACC/AHA Task Force on Clinical Data Standards
established the Writing Committee in November 2012,
according to the processes described in the Task Force
on Clinical Data Standards’ methodology statement (15).
As described previously, the responsibility of the
Writing Committee was to review and reﬁne the list of
candidate terms identiﬁed by the SCTI and to harmo-
nize the attributes and other informatics formalisms
required to attain interoperability of the terms. During
the ﬁrst 6 months of 2013, the work of the Writing
Committee was accomplished through a series of tele-
conference and Web conference meetings, along with
extensive correspondence by e-mail. The review work
was distributed among subgroups of the Writing Com-
mittee on the basis of their interest and expertise in
the components of the terminology set. The proceedings
of the work groups were then assembled, resulting in
the vocabulary and associated descriptive prose in
Section 3. All members reviewed and approved the ﬁnal
vocabulary.
2.6. Relation to Other Standards
The Writing Committee reviewed the work of the SCTI
along with available published data standards, speciﬁ-
cally those developed for death, acute myocardial
infarction, stroke, TIA, unstable angina/non–ST-elevation
myocardial infarction, HF, PCI, and peripheral vascular
intervention (4–13,16–21). Existing published deﬁnitions
were adjusted to eliminate verbiage not relevant to an
actual deﬁnition (e.g., instructions such as the phrase
“indicate whether the patient has.” have been
eliminated).
Through the afﬁrmation and reﬁnement of existing
data standards, the Writing Committee anticipates that
the vocabulary will facilitate the uniform adoption of
these terms, where appropriate, by the clinical care,clinical and translational research, regulatory, quality and
outcomes, and EHR communities.
2.7. Peer Review, Public Review, and Board Approval
The “2014 ACC/AHA Key Data Elements and Deﬁnitions
for Cardiovascular Endpoint Events in Clinical Trials”
statement was reviewed by ofﬁcial reviewers nominated
by the ACC and AHA. To increase its applicability further,
the document was posted on the ACC Web site for a
30-day public comment period. This document was
approved for publication by the ACC Board of Trustees on
November 12, 2014, and by the AHA Science Advisory and
Coordinating Committee on June 13, 2014. The Writing
Committee anticipates that these data standards will
require review and updating in the same manner as other
published guidelines, performance measures, and appro-
priate use criteria. The Writing Committee will therefore
review the set of data elements periodically, starting
with the anniversary of publication of the standards, to
ascertain whether modiﬁcations should be considered.
3. DATA ELEMENTS AND DEFINITIONS
As described above, the SCTI identiﬁed candidate car-
diovascular and stroke endpoint event terms in the draft
document “Standardized Deﬁnitions for Cardiovascular
and Stroke Endpoint Events in Clinical Trials.” The
document delineated the following cardiovascular and
neurological endpoint events in the context of clinical
trials and regulatory reporting:
1. Cardiovascular death
2. Noncardiovascular death
3. Undetermined cause of death
4. Myocardial infarction
5. Hospitalization for unstable angina
6. Transient ischemic attack and stroke
7. Heart failure event
8. Percutaneous coronary intervention
9. Peripheral vascular intervention
10. Stent thrombosis
The SCTI envisioned that data collection and exchange
standards for these endpoint events would allow indi-
vidual investigators and clinical research organizations
to collect and exchange research data consistently and
efﬁciently. It also envisioned that adoption of the
controlled terminology within the research and regula-
tory sectors could facilitate consistency across the clinical
care domain.
3.1. Death Attribution
Death is classiﬁed into 1 of 3 categories: 1) cardiovascular
death; 2) noncardiovascular death; and 3) undetermined
cause of death. The intent of the classiﬁcation schema is
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underlying cause of death. The key priority is differenti-
ating between cardiovascular and noncardiovascular
causes of death (Appendix 3).
Collection of appropriate source documentation is
critical for rigorous adjudication of the cause of death.
Although death certiﬁcates establish that the patient
died, reliance on information included in death certiﬁ-
cates may be problematic; several studies have demon-
strated inaccurate coding in the death certiﬁcate when
death certiﬁcates were compared with adjudicated out-
comes (22,23). In contrast, autopsy reports are often
valuable in assessing the cause of death and should be
used whenever possible.
For sudden deaths, even when witnessed, death attri-
bution may be difﬁcult if only limited information is
available. Frequently, these deaths are attributed to
either sudden cardiac death (cardiovascular death) or
death due to an undetermined cause. Sensitivity analyses
may be helpful in determining the effect of these events
on the primary and major secondary endpoints in a
particular clinical trial or development program.
3.1.1. Cardiovascular Cause of Death
Frequently, the cardiovascular death category is not
divided further into subcategories such as death resulting
from an acute myocardial infarction, sudden cardiac
death, or HF, because the cause of death is so often un-
known or ambiguous (e.g., Does a death after a myocar-
dial infarction count as a myocardial infarction, sudden
death, arrhythmic death, or HF death?). Moreover, the
underlying cause of death and the mode of death (i.e.,
most proximate event associated with death) may overlap
substantially. In contrast, precision is more achievable
with respect to nonfatal events.
However, in cases where subclassiﬁcation is desired,
the Writing Committee recommends a uniform approach
for categorizing the attributable cause (and not just the
proximate event) for cardiovascular death. The suggested
subcategories for attribution of death to a cardiovascular
etiology are acute myocardial infarction, sudden cardiac
death, HF, stroke, cardiovascular procedure, cardio-
vascular hemorrhage, and other cardiovascular causes.
“Death due to other cardiovascular causes” refers to a
cardiovascular death not included in the above categories
but with a speciﬁc known cause, such as a pulmonary
embolism or peripheral arterial disease. In addition,
“death due to cardiovascular hemorrhage” refers to a
death related to hemorrhage such as a nonstroke intra-
cranial hemorrhage, nonprocedural or nontraumatic
vascular rupture (e.g., aortic aneurysm), or pulmonary
hemorrhage from a pulmonary embolism. In contrast,
if a pulmonary hemorrhage were a result of a contusion
from a motor vehicle accident, the cause of deathwould be noncardiovascular (death due to trauma).
Although these subcategories may not be applicable to
all study populations, therapeutic areas, or drug and
device development programs, the events in these sub-
categories occur relatively frequently in the general
population and probably contribute to mortality in any
observation. In some trials, subclassiﬁcation of cardio-
vascular causes of death may prove helpful in under-
standing pathophysiology in the context of drug or
device programs.
3.1.2. Noncardiovascular Cause of Death
Identifying noncardiovascular causes of death is impor-
tant when assessing competing mortality risks in both
cardiovascular and noncardiovascular trials. The pro-
posed schema for noncardiovascular causes of death is
more general than that for cardiovascular causes of death.
This noncardiovascular schema could be expanded to
capture other causes for speciﬁc trials in particular ther-
apeutic areas or for speciﬁc drug or device development
programs if a speciﬁc toxicity has been identiﬁed in
nonclinical work or early clinical trials. When death is
clearly due to a noncardiovascular cause, a cardiovascular
cause of death is excluded. The proposed values repre-
sent commonly used noncardiovascular categories.
3.1.3. Undetermined Cause of Death
In general, this category of death should apply to few
patients in well-run clinical trials. Attribution of causal-
ity may be limited or impossible if information available
at the time of death is minimal or nonexistent. In such
cases, the date of death may be the only data element
captured.
The key priority is to prespecify how these deaths
will be classiﬁed and to implement a uniform approach
throughout the conduct of the trial. Occasionally, it may
not be possible to determine exact causality when 2 lethal
conditions contribute to death equally. In this circum-
stance, 1 condition should be chosen, with consideration
of the issue being studied. For example, if cardiac safety
is under consideration and the competing causes of
death are cardiovascular and noncardiovascular, cardio-
vascular death should take precedence.
3.2. Myocardial Infarction
The categorization and deﬁnitions of the types of
myocardial infarction are derived from the “Third Uni-
versal Deﬁnition of Myocardial Infarction” (13,14), the
“2012 ACCF/AHA Guideline for the Management of Un-
stable Angina/Non-ST-Elevation Myocardial Infarction”
(12), and the “2013 ACCF/AHA Guideline for the Manage-
ment of ST-Elevation Myocardial Infarction” (18).
The key recommendation is to base thresholds
for biomarker detection of myocardial infarction on
Hicks et al. J A C C V O L . 6 6 , N O . 4 , 2 0 1 5
Cardiovascular Endpoints Data Standards J U L Y 2 8 , 2 0 1 5 : 4 0 3 – 6 9
41099th percentile values (i.e., the upper reference limit)
rather than on “upper limit of normal” values. Multiple
assays exist for cardiac troponin and the MB fraction of
creatine kinase (CK-MB), and assay characteristics vary by
manufacturer. Some assays reported by local laboratories
provide the 99th percentile and a higher “decision limit”
or upper limit of normal above which myocardial infarc-
tion should be considered. The “Third Universal Deﬁni-
tion of Myocardial Infarction” (13,14) recommends the
use of the 99th percentile upper reference limit as the
reference standard. The data elements developed in
Appendix 4 allow both the 99th percentile and the upper
limit of normal (or both) to be captured, depending on the
reporting approach used in the central or local laboratory.
Instead of listing every cardiac biomarker assay in
Appendix 4, we have elected to represent all assays with
the generic term [cardiac biomarker]. The actual
biomarker assay used should replace the generic term
[cardiac biomarker]. Collection of serial biomarker values
to capture all measurements (and to reﬂect rise or fall of
the biomarker) would recursively use the same data
element construct as the approach for capturing a single
value. Cardiac troponin is the preferred biomarker. If
troponin values are not available, then CK-MB mass is
used as an alternative.
The terminology set includes data elements for stent
restenosis without occlusion as a type of acute myocardial
infarction (type 4c) and asymptomatic postbaseline
myocardial infarction detected during follow-up. The
data elements that reﬂect old or prior myocardial infarc-
tion at baseline are not included here but can be found in
the “2013 ACCF/AHA Key Data Elements and Deﬁnitions
for Measuring the Clinical Management and Outcomes of
Patients With Acute Coronary Syndromes and Coronary
Artery Disease” (16).
The Writing Committee acknowledges that there is
disagreement about how to deﬁne a “clinically relevant
myocardial infarction” after coronary revascularization
(PCI or coronary artery bypass graft). An expert consensus
group from the Society for Cardiovascular Angiography
and Interventions (24) proposes the use of CK-MB instead
of troponin and different cut points from those included
in the “Third Universal Deﬁnition of Myocardial Infarc-
tion” (13,14). A detailed discussion of these differences is
beyond the scope of this publication but is provided by
White (25). At this time, the Writing Committee continues
to support the “Third Universal Deﬁnition of Myocardial
Infarction” (13) for harmonization purposes but recog-
nizes that this matter requires further study. As long
as cardiac biomarker values (both cardiac troponin and
CK-MB) and 99th percentile upper reference limit values
are recorded, virtually any deﬁnition of periprocedural
myocardial infarction can be applied and examined with
respect to outcome.3.3. Hospitalization for Unstable Angina
Hospitalization for unstable angina is a commonly used
endpoint in clinical trials evaluating the efﬁcacy or
safety of cardiovascular therapies such as lipid-modifying
agents, antihypertensive drugs, antithrombotic therapies,
and coronary interventions. Unlike traditional endpoints
such as death, myocardial infarction, or stroke, hospital-
ization for unstable angina, by necessity, involves some
degree of subjective assessment of the most likely etiol-
ogy of symptoms resulting in hospital admission. The
terminology set for unstable angina (Appendix 5) focuses
on data elements needed for determining whether
symptoms truly represent cardiovascular ischemia, in-
cluding the character and duration of the presenting
symptoms, the proximity of symptom onset to hospitali-
zation, and the duration of hospitalization. Electrocar-
diographic abnormalities are pivotal to the diagnosis.
Such abnormalities include the presence or absence of
deviations in the ST segment, morphology of ST-segment
changes (horizontal or downsloping versus upsloping),
and the magnitude of the deviation. Many patients
without high-risk features (i.e., patients with low TIMI
[Thrombolysis in Myocardial Infarction] or GRACE [Global
Registry of Acute Coronary Events] risk scores) undergo
provocative testing for inducible myocardial ischemia,
requiring measurement of ST elevation or depression
during electrocardiographic monitoring. Alternatively,
exercise or pharmacological stress testing may involve
assessment of wall motion abnormalities on echocar-
diography and/or reversible perfusion defects by nuclear
scintigraphy or magnetic resonance imaging. Other im-
portant data elements include angiographic evidence of
the severity of coronary stenosis or presence of coronary
thrombus in a vessel believed to be responsible for the
ischemic signs and symptoms. Additional data elements
include the need for coronary revascularization by PCI or
coronary bypass surgery of lesion(s) believed responsible
for the hospitalization.
The need for escalation of pharmacological therapy
(nitrates, beta-blockers, or other antianginal therapy)
may provide supportive evidence for a diagnosis of
unstable angina. Last, to fulﬁll the criteria for un-
stable angina, cardiac biomarkers must be negative
and there can be no evidence of acute myocardial
infarction.
3.4. Transient Ischemic Attack and Stroke
TIA and stroke endpoints (Appendix 6) are designed to
capture the incidence of new TIA and stroke, type of
stroke (i.e., ischemic, hemorrhagic, or undetermined),
and severity of stroke (i.e., mortality and level of func-
tional disability). The modiﬁed Rankin Scale (26) is rec-
ommended as the measure of disability. Hemorrhagic
stroke may be further subcategorized as intracerebral
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sufﬁcient information to make this determination.
The Writing Committee proposes the following deﬁni-
tion of TIA: “a transient episode of focal neurological
dysfunction caused by brain, spinal cord, or retinal
ischemia, without acute infarction.” This deﬁnition is
identical to that adopted by the SCTI (FDA Stroke Team)
and is based on one previously proposed in an AHA/
American Stroke Association (ASA) scientiﬁc statement
(9) with one subtle but important difference: as deﬁned
by the scientiﬁc statement, TIA is “a transient episode of
neurological dysfunction caused by focal brain, spinal
cord, or retinal ischemia, without acute infarction.” The
SCTI deﬁnition that the Writing Committee has adopted
emphasizes the clinical presentation rather than the
anatomic location of the TIA and may be more appropriate
for clinical trial use because the availability of imaging
modalities may vary greatly from one study center to
the next.
In contrast to TIA, stroke is deﬁned on the basis of the
presence of acute infarction as demonstrated by imaging
or based on the persistence of symptoms. The Writing
Committee acknowledges that the categorization of TIA
versus ischemic stroke depends partly on the sensitivity
of the diagnostic assessments for brain infarction. For
example, patients with symptoms of short duration
(e.g., <24 hours) but evidence of infarction on magnetic
resonance imaging could be categorized as having had an
ischemic stroke. In contrast, in the absence of highly
sensitive magnetic resonance imaging evidence, the same
patient could be categorized as having had a TIA. The
presence of persisting symptoms should be considered
sufﬁcient evidence for stroke rather than TIA. Primarily
on the basis of consensual practice (rather than objective
evidence), the AHA/ASA has recommended the existence
of symptoms for at least 24 hours as an operational deﬁ-
nition of persisting symptoms to indicate stroke rather
than TIA (19). However, the time cut point that best dis-
criminates between infarction and the absence of infarc-
tion remains largely undeﬁned. Accordingly, for any
clinical trial that plans to use the duration of symptom
persistence to operationally discriminate between TIA
and stroke, the Writing Committee and SCTI recommend
prespecifying the particular duration in the protocol,
although both acknowledge that a duration $24 hours
is frequently used.
Depending on the trial objectives, additional optional
information could be recorded for analysis, including
physical examination ﬁndings (e.g., using the AHA/ASA
guideline–recommended National Institutes of Health
Stroke Scale), presumed mechanism of ischemic stroke,
and impact on additional patient-centered outcomes
such as basic or instrumental activities of daily living.
Investigators interested in collecting more detailedinformation on stroke outcomes should consider using
the National Institute of Neurological Disorders
and Stroke Common Data Elements, available online at
www.commondataelements.ninds.nih.gov.
3.5. Heart Failure Event
HF is a common outcome of many different etiologies and
may be associated with cardiovascular and non-
cardiovascular treatment modalities. Accurate recogni-
tion of HF events is important because of the poor
outcomes associated with them and because of their
increasing prevalence and societal burden. In clinical tri-
als, when a speciﬁc uniform deﬁnition is lacking, the
concurrence between the initial and adjudicated assess-
ment of HF is lower than is the case with adjudications of
myocardial infarction and/or stroke (27). This lack of
concurrence illustrates the challenges investigators face
in classifying HF events and underlines the importance
of a standardized deﬁnition of event. A consistent deﬁ-
nition will ensure that all HF events are accurately
reported in all clinical trials and registries.
The proposed HF endpoint event (Appendix 7) has
been constructed independent of whether the exacerba-
tion of HF results in hospitalization, recognizing that
exacerbation of HF can often be managed on an out-
patient basis such as with an urgent or unscheduled
outpatient ofﬁce/practice or emergency room visit.
Instead, the key characteristic of a HF event is the need
for a resource-intensive response to failure of the primary
therapeutic management strategy. The terminology set
for a HF event requires both subjective and objective
ﬁndings, including worsening symptoms and signs, as
well as laboratory evidence supporting the diagnosis of
worsening HF. Also incorporated into the deﬁnition is
the requirement for a substantive intensiﬁcation in HF
therapies, whether pharmacological, mechanical, or both.
For additional details, see Appendix 8 (28–40).
3.6. Percutaneous Coronary Intervention
The vast majority of catheter-based interventional cardi-
ology procedures are performed to treat atherosclerotic
coronary artery lesions.
For coronary revascularization procedures, it is
important to determine whether the procedure was per-
formed to treat symptoms of myocardial ischemia or
based solely on coronary anatomic characteristics. It is
also important to document whether the Heart Team
considered the patient to be inappropriate for surgical
revascularization due to prohibitive comorbidities. Med-
ical records that include a description of symptoms and
objective assessments of ischemia should be reviewed
to determine whether the revascularization procedure
was clinically indicated. Imaging reviews by indepen-
dent core laboratories (e.g., angiography, intravascular
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particularly useful for reducing potential bias.
The terminology set for PCI (Appendix 9) concentrates
on PCI status, procedural success, target lesion failure,
target lesion revascularization, and both intraprocedural
and vascular complications. Of speciﬁc note, the Writing
Committee identiﬁed limitations in the nomenclature of
the coronary arteries as described for the Coronary Artery
Surgery Study (CASS) (41), which has subsequently been
updated by the Bypass Angioplasty Revascularization In-
vestigators (BARI) (42) and is currently used by the ACC
National Cardiovascular Data Registry. For example, the
nomenclature does not address the concepts of ostial or
bifurcation disease and does not follow a consistent
convention for naming coronary segments. The Writing
Committee therefore proposes an update to the CASS/
BARI/National Cardiovascular Data Registry coronary
artery nomenclature (Appendix 10) to better capture data
evaluating treatment approaches to ostial and bifurcation
disease, improve the consistency and completeness of
coronary artery nomenclature, include the Medina Clas-
siﬁcation (43,44) as a standard, and reﬂect universal
conventions and terminology currently used by angiog-
raphy core laboratories. Finally, as new classes of
intracoronary therapy (e.g., drug-coated balloons, bio-
resorbable drug-eluting stents/scaffolds) are developed,
novel mechanisms of failure may be identiﬁed that will
require modiﬁcation and addition to this controlled
vocabulary.
3.7. Peripheral Vascular Intervention
Peripheral artery disease (PAD) is widespread. Of all the
atherosclerotic syndromes, the clinical relevance of PAD
is poorly appreciated by primary care physicians, cardio-
vascular specialists, and patients alike. Not only does
PAD reduce the physical functioning of affected patients,
but it is associated with a marked increase in all-cause
and cardiovascular mortality.
Although vascular disease is deﬁned as “all diseases
of the arteries, veins, and lymphatic vessels” (10), for
simplicity, this vocabulary for peripheral vascular inter-
vention endpoints focuses on data elements that describe
revascularization interventions involving the peripheral
arterial circulation. These data standards concentrate
on PAD involving the infrarenal aorta, iliac, and infrain-
guinal arteries and carotid, renal, mesenteric, and aortic
interventions. Of note, upper extremity or intracranial
vascular diseases are beyond the scope of this
publication.
Appendix 11 lists the vocabulary to facilitate uniform
reporting of endovascular and surgical interventions for
patients with PAD, thereby allowing comparisons of drug,
device, and surgical treatments for PAD. Included are
harmonized deﬁnitions of success and failure that arederived from the coronary revascularization terminology,
including concepts of target lesion and target vessel
revascularization. Although somewhat arbitrary, the
proposed construct includes the division of the lower
extremity arterial circulation into the 3 “vessel” terri-
tories, or levels (aorto-iliac, femoral-popliteal, and tibio-
peroneal) analogous to the division of the 3 coronary
vessel territories.
As new classes of endovascular therapy (e.g., drug-
coated balloons, bioresorbable drug-eluting stents/scaf-
folds) are developed, novel mechanisms of failure may
be identiﬁed that will require modiﬁcation and addition
to this controlled vocabulary.
3.8. Stent Thrombosis
According to the classiﬁcation proposed by the Academic
Research Consortium, stent thrombosis is deﬁned as
deﬁnite, probable, or possible (7). Deﬁnite stent thrombosis
is deﬁned as occurring when clinical presentation is
consistent with acute coronary syndrome and angiog-
raphy or autopsy examination conﬁrm stent occlusion or
thrombus. Probable stent thrombosis is deﬁned as death
occurring within 30 days that cannot be attributed to
another cause or when myocardial infarction occurs at any
time point and is attributable to the target vessel in
the absence of angiography conﬁrming another culprit
lesion. Finally, possible stent thrombosis is deﬁned as
occurring when the patient dies after >30 days and death
is not explained by another cause. The terminology set
(Appendix 9) focuses on data elements required for
conﬁrmation of stent thrombosis. To classify these events
accordingly, the following information is required: clinical
details surrounding the acute event; dates and procedural
information for all prior stent procedures; serial electro-
cardiograms at the time of the event and for appropriate
duration of follow-up; serial cardiac biomarkers; results of
coronary angiography with review by an independent
angiographic core laboratory or independent clinical
events committee; and clinical details surrounding all
deaths, including death certiﬁcate and autopsy report if
applicable. When available data support >1 classiﬁcation,
the highest level of certainty should be reported.
4. INFORMATICS OF CONTROLLED
VOCABULARIES
Variability in the deﬁnitions, formatting, and encoding of
clinical concepts hinders the use, exchange, and analysis
of information in health care. Efﬁcient use of healthcare
information requires both syntactic interoperability (i.e.,
standards and protocols for formatting, packaging, and
transmission required for computer-to-computer data
transfer) and semantic interoperability (i.e., the capacity
of computer systems to transmit data with unambiguous,
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413shared meaning, enabling machine-computable logic, data
federation, inferential processing, and knowledge discov-
ery) (45,46). To achieve these forms of interoperability,
the Writing Committee speciﬁed the attributes of the
endpoint concepts relevant to the informatics of con-
trolled vocabularies. These attributes (terminology
concept, concept deﬁnition, permissible values, permis-
sible value deﬁnitions) are only a subset of those needed to
characterize data elements. Other attributes are still
needed to fully qualify a terminology set as a controlled
vocabulary; these include preferred abbreviation, concept
unique identiﬁer, data type, data format, relationships to
other terms, use of case context describing where and
when a concept is assessed, and concept steward. The
need to be explicit is particularly relevant because the
class of endpoint events represents summative concepts
more useful for assessing responses and outcomes to
therapeutic approaches and treatments. The use of sum-
mative concepts contrasts with the emphasis in EHR
solutions on diagnoses as classiﬁed by taxonomies such
as the International Classiﬁcation of Disease and the
Systemized Nomenclature of Medicine—Clinical Terms.
Under FDA grant 1R24FD004411-01, this terminology
set has been developed as a controlled vocabulary in the
cardiovascular domain of the Clinical Data Acquisition
and Standards Harmonization, and the tabular repre-




MASTER.xlsx. The terminology set will also be devel-
oped in an International Organization for Standardiza-
tion/International Electrotechnical Commission 11179
standard metadata repository; this speciﬁcation pro-
vides a standardized grammar and syntax for describing
data elements and associated metadata, resulting in
unambiguous representation and interpretation of data
(47,48). Speciﬁcally, the endpoint concepts will be rep-
resented in the National Institutes of Health/NationalCancer Institute Data Standards Registry and Repository
to facilitate the use of the terminology set across the
clinical care, research, and regulatory domains. Finally, it
is intended for this terminology set to be developed and
balloted through the HL7 EHR System Functional Model
process to further foster adoption in EHR systems.
The Writing Committee acknowledges that cardiovas-
cular and stroke endpoint event concepts are a subset of
a larger set of cardiovascular endpoints. In particular,
additional concepts such as those describing carotid/
cerebral revascularization, peripheral surgical revascu-
larization, aortic dissection, abdominal aortic aneurysm,
aortic surgery, and valvular heart disease remain to be
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Element Label Permissible Values Permissible Value Deﬁnit Citations and References
Death—System
Attribution
Classiﬁcation of the cause
of death by physiological
system.
Note: Classiﬁcation may










Primary Cause of Death  CV: acute MI
 CV: sudden cardiac death
 CV: HF
 CV: stroke
 CV: CV procedure











 Non-CV procedure or surgery
 Trauma
 Suicide
 Nonprescription drug reaction or
overdose






CV: acute MI Death by any cardiovascular mechanism a,
sudden death, HF, stroke, pulmonary em )
within 30 d after an acute MI, related to iate
consequences of the MI, such as progre
recalcitrant arrhythmia. There may be a
(attributable) mechanisms of cardiovasc
during this time period, but for simplicit
cardiovascular death occurs within 30 d MI,
it will be considered a death due to MI.
Note: Acute MI should be veriﬁed to the sible
by the diagnostic criteria outlined for ac y
autopsy ﬁndings showing recent MI or r ary
thrombosis. Death resulting from a proce t an
MI (PCI or CABG), or to treat a complica ng
from MI, should also be considered dea ute
MI. Death resulting from an elective coro dure
to treat myocardial ischemia (i.e., chroni ina)
or death due to an MI that occurs as a d
consequence of a cardiovascular investig
procedure/operation should be consider th
due to a cardiovascular procedure.
Continued on the next page






































































Element Label Permissible Values Permissible Value Deﬁnitions Citations and References
CV: sudden cardiac death Death that occurs unexpectedly and not within 30 d of
an acute MI.
Note: Sudden cardiac death includes the following
scenarios:
 Death witnessed and occurring without new or
worsening symptoms
 Death witnessed within 60 min of the onset of
new or worsening cardiac symptoms unless the
symptoms suggest acute MI
 Death witnessed and attributed to an identiﬁed
arrhythmia (e.g., captured on an electrocardio-
graphic recording, witnessed on a monitor, or
unwitnessed but found on ICD review)
 Death after unsuccessful resuscitation from car-
diac arrest (e.g., ICD unresponsive sudden cardiac
death, pulseless electrical activity arrest)
 Death after successful resuscitation from cardiac
arrest and without identiﬁcation of a speciﬁc
cardiac or noncardiac etiology
 Unwitnessed death in a subject seen alive and
clinically stable #24 h before being found dead
without any evidence supporting a speciﬁc non-
cardiovascular cause of death (information about
the patient’s clinical status preceding death
should be provided if available)
Unless additional information suggests an alternate
speciﬁc cause of death (e.g., Death due to Other Car-
diovascular Causes), if a patient is seen alive #24 h
before being found dead, sudden cardiac death (criterion
2f) should be recorded. For patients who were not
observed alive within 24 h of death, undetermined cause
of death should be recorded (e.g., a subject found dead
in bed but who had not been seen by family members for
>24 h).
CV: HF Death associated with clinically worsening symptoms
and/or signs of HF, regardless of HF etiology
Note: Deaths due to HF can have various etiologies,
including single or recurrent MIs, ischemic or
nonischemic cardiomyopathy, hypertension, or valvular
disease.
CV: stroke Death after a stroke that is either a direct consequence
of the stroke or a complication of the stroke.
Note: Acute stroke should be veriﬁed to the extent
possible by the diagnostic criteria outlined for stroke.




















































Element Label Permissible Values Permissible Value Deﬁ Citations and References
CV: CV procedure Death caused by the immediate com a
Cardiovascular procedure
CV: CV hemorrhage Death related to hemorrhage such a
intracranial hemorrhage (e.g., subdu
nonprocedural or nontraumatic vasc g.,
aortic aneurysm), or hemorrhage ca
tamponade
CV: other Cardiovascular death not included in
categories but with speciﬁc, known c AD)
Pulmonary Noncardiovascular death attributabl the
lungs (excludes malignancy)
Renal Noncardiovascular death attributabl e
Gastrointestinal Noncardiovascular death attributabl the
esophagus, stomach, or intestines (e
malignancy)
Hepatobiliary Noncardiovascular death attributabl the
liver, gall bladder, or biliary ducts (ex ncy)
Pancreatic Noncardiovascular death attributabl the
pancreas (excludes malignancy)






inﬂammatory or immune-mediated d ss
Note: Includes SIRS, immunological, ne
diseases and disorders. Includes ana
environmental (e.g., food) allergies.
Hemorrhage Noncardiovascular death attributable at is
not considered cardiovascular hemo
according to this classiﬁcation schem
Non-CV procedure or surgery Death caused by the immediate com a
noncardiovascular procedure or surg
Trauma Noncardiovascular death attributabl
Includes homicide.
Suicide Noncardiovascular death attributabl
Nonprescription drug reaction or
overdose
Noncardiovascular death attributabl
nonprescription drug reaction or ove























































ause (e.g., PE, P
e to disease of
e to renal failur
e to disease of
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e to disease of
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Element Label Permissible Values Permissible Value Deﬁnitions Citations and References
Prescription drug reaction or overdose Noncardiovascular death attributable to a prescription
drug reaction or overdose.
Note: Includes anaphylaxis.
Neurological Noncardiovascular death attributable to disease of the
nervous system (excludes malignancy).
Note: Excludes cardiovascular death from ischemic
stroke, hemorrhagic stroke, or undetermined cause of
stroke, or cardiovascular hemorrhage of central nervous
system
Malignancy Noncardiovascular death attributable to leukemia,
lymphoma, or other malignancy.
Other non-CV; specify Noncardiovascular death attributable to a cause other




Date and time of death Death Date_Time  Date–time
CABG indicates coronary artery bypass graft; CV, cardiovascular; HF, heart failure; ICD, implantable cardioverter-deﬁbrillator; MI, myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; PE, pulmonary embolism;

















































Terminology Concept Concept Deﬁnition
Suggested Data
Element Label Permissible Values Permissible Value Deﬁnitions Citations and References
Acute MI Clinical syndrome where there
is evidence of myocardial







Thygesen K, Alpert JS, Jaffe AS, et al.
Third universal deﬁnition of myocardial
infarction. J Am Coll Cardiol.
2012;60:1581–98 (14).
Thygesen K, Alpert JS, Jaffe AS, et al.
Third universal deﬁnition of myocardial
infarction. Circulation. 2012;126:2020–
35 (13).






Acute MI—Type Type of acute MI, classiﬁed
according to the Joint ESC/
ACCF/AHA/WHF Joint Task
Force for the Universal
Deﬁnition of Myocardial
Infarction.
Note: cTn-I or -T is the
preferred biomarker. If a cTn
assay is not available, the best
alternative is CK-MB
(measured by mass assay).
Acute Myocardial
Infarction Type
 Type 1: spontaneous
 Type 2: ischemic
imbalance
 Type 3: death, no
biomarkers
 Type 4a: PCI related
 Type 4b: stent
thrombosis
 Type 4c: stent
restenosis
 Type 5: CABG related
Thygesen K, Alpert JS, Jaffe AS, et al.
Third universal deﬁnition of myocardial
infarction. J Am Coll Cardiol.
2012;60:1581–98 (14).
Thygesen K, Alpert JS, Jaffe AS, et al.
Third universal deﬁnition of myocardial
infarction. Circulation. 2012;126:2020–
35 (13).
Type 1: spontaneous Spontaneous clinical syndrome related to atherosclerotic
plaque rupture, ulceration, ﬁssuring, erosion, or dissection,
with resulting intraluminal thrombus, and leading to
decreased myocardial blood ﬂow or distal platelet emboli
with ensuing myocyte necrosis. This classiﬁcation requires
a) Detection of a rise and/or fall of [cardiac biomarker]
values (preferably cTn) with at least 1 value >99th
percentile of the URL and
b) At least 1 of the following:
1) Symptoms of myocardial ischemia
2) New or presumed new signiﬁcant ST-segment–
T wave (ST–T) changes or new LBBB on the ECG
3) Development of pathological Q waves on the ECG
4) Imaging evidence of new loss of viable myocardium
or new regional wall motion abnormality
5) Identiﬁcation of an intracoronary thrombus by
angiography or autopsy.
Notes: One or more coronary arteries may be involved. The
patient may have underlying severe CAD but on occasion
may have nonobstructive CAD.
Continued on the next page
















































Terminology Concept Concept Deﬁnition
Suggested Data
Element Label Permissible Values Permissible Value Deﬁnitions Citations and References
Type 2: ischemic
imbalance
Spontaneous clinical syndrome where a condition other than
CAD contributes to an imbalance between myocardial
oxygen supply and/or demand (e.g., coronary endothelial
dysfunction, coronary artery spasm, coronary embolism,
tachy-/bradyarrhythmias, anemia, respiratory failure,
hypotension, and hypertension with or without LVH). This
classiﬁcation requires
a) Detection of a rise and/or fall of [cardiac biomarker]
values (preferably cTn) with at least 1 value >99th
percentile of the URL and
b) At least 1 of the following:
1) Symptoms of myocardial ischemia
2) New or presumed new signiﬁcant ST-segment–
T wave (ST–T) changes or new LBBB on the ECG
3) Development of pathological Q waves on the ECG
4) Imaging evidence of new loss of viable myocardium
or new regional wall motion abnormality.
Type 3: death, no
biomarkers
Death where symptoms suggestive of myocardial ischemia
are present, and with (presumed) new ischemic changes or
new LBBB on ECG, but where death occurs before cardiac
biomarkers can be obtained or could rise or (in rare cases)
were not collected.
Type 4a: PCI related MI associated with and occurring within 48 h of PCI, with
elevation of cardiac biomarker values to >5  99th
percentile of the URL in patients with normal baseline values
(#99th percentile URL), or a rise of [cardiac biomarker]
values $20% if baseline values are elevated and are stable
or falling. This classiﬁcation also requires at least 1 of the
following:
a) Symptoms suggestive of myocardial ischemia
(i.e., prolonged ischemia $20 min)
b) New ischemic changes on ECG or new LBBB
c) Angiographic loss of patency of a major coronary
artery or a side branch or persistent slow ﬂow or no
ﬂow or embolization
d) Imaging evidence of new loss of viable myocardium or
new regional wall motion abnormality.
Type 4b: stent
thrombosis
MI associated with stent thrombosis as detected by coronary
angiography or at autopsy, where symptoms suggestive of
myocardial ischemia are present, and with a rise and/or fall
of [cardiac biomarker] values, with at least 1 value >99th
percentile of the URL.

















































Terminology Concept Concept Deﬁnition
Suggested Data
Element Label Permissible Values Permissible Value Deﬁni Citations and References
Type 4c: stent restenosis MI associated with stent restenosis as de ronary
angiography or at autopsy, occurring >48 ,
without evidence of stent thrombosis bu oms
suggestive of myocardial ischemia, and w of
[cardiac biomarker] values to >99th perc URL.
This classiﬁcation also requires the follow
a) Does not meet criteria for any other n
of MI
b) Presence of a $50% stenosis at the ious
successful stent PCI or a complex le other
signiﬁcant obstructive CAD of great
following
1) Initially successful stent deploym
2) Dilation of a coronary artery sten alloon
angioplasty to <50% stenosis
Note: Type 4c is described in the text of t iversal
Deﬁnition of Myocardial Infarction.”
Type 5: CABG related MI associated with and occurring within 4
surgery, with elevation of [cardiac bioma to
>10  99th percentile of the URL in pat rmal
baseline cardiac biomarker values (#99th RL).
This classiﬁcation also requires at least 1 ing:
a) New pathological Q waves, new LBB
b) Angiographic new graft or new nativ artery
occlusion
c) Imaging evidence of new loss of viab ium or
new regional wall motion abnormal
Acute MI—Symptoms,
Acute
Presence of acute symptoms
of myocardial ischemia, such
as chest, upper extremity,
mandibular, or epigastric
discomfort, or an ischemic
equivalent such as dyspnea or
fatigue. This is one of the
noncardiac marker criteria
supporting the diagnosis of







Thygesen K, Alpert JS, Jaffe AS, et al.
Third universal deﬁnition of myocardial
infarction. J Am Coll Cardiol.
2012;60:1581–98 (14).
Thygesen K, Alpert JS, Jaffe AS, et al.





Date and time of onset of
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Terminology Concept Concept Deﬁnition
Suggested Data




Presence of new or presumed
new signiﬁcant ST-segment–T
wave (ST-T) changes or new
LBBB consistent with acute
myocardial ischemia. This is
one of the noncardiac marker
criteria supporting the
diagnosis of acute MI types 1,
2, 3, and 4.
Acute Ischemic ECG
Change Type
 Ischemic changes on
ECG
 LBBB
Thygesen K, Alpert JS, Jaffe AS, et al.
Third universal deﬁnition of myocardial
infarction. J Am Coll Cardiol.
2012;60:1581–98 (14).
Thygesen K, Alpert JS, Jaffe AS, et al.
Third universal deﬁnition of myocardial
infarction. Circulation. 2012;126:2020–
35 (13).
Ischemic changes on ECG In the absence of LVH and LBBB pattern (or other
confounder such as a paced rhythm) on ECG, either a) new
(or presumed new) ST elevation at the J point in 2
contiguous leads with the following cut points: $0.1 mV in
all leads other than leads V2 to V3 where the following cut
points apply: $0.2 mV in men $40 y of age; $0.25 mV in
men <40 y of age, or $0.15 mV in women; or b) new (or
presumed new) horizontal or downsloping ST-segment
depression $0.05 mV in 2 contiguous leads and/or T
inversion $0.1 mV in 2 contiguous leads with prominent R
wave or R/S ratio >1.
LBBB New (or presumed new) LBBB pattern on ECG.
Acute MI—New Q Waves
on ECG
Presence of new or presumed
new pathological Q waves
consistent with MI. This is one
of the noncardiac marker
criteria supporting the
diagnosis of acute MI types 1,
2, 4, and 5.
ECG Change, New
Q-Wave Indicator
 New Q waves New (or presumed new) a) Q wave in leads V2 to
V3 $0.02 s or QS complex in leads V2 and V3; b) Q
wave $0.03 s and $0.1 mV deep or QS complex in leads I, II,
aVL, aVF, or V4 to V6 in any 2 leads of a contiguous lead
grouping (I, aVL; V1 to V6; II, III, aVF; V7 to V9); or c) R
wave $0.04 s in V1 to V2 and R/S $1 with a concordant
positive T wave in the absence of a conduction defect.
Thygesen K, Alpert JS, Jaffe AS, et al.
Third universal deﬁnition of myocardial
infarction. J Am Coll Cardiol.
2012;60:1581–98 (14).
Thygesen K, Alpert JS, Jaffe AS, et al.





Presence of thrombus in a
major epicardial vessel
consistent with an acute MI.
This is one of the noncardiac
marker criteria supporting the








 Thrombus at autopsy
Thygesen K, Alpert JS, Jaffe AS, et al.
Third universal deﬁnition of myocardial
infarction. J Am Coll Cardiol.
2012;60:1581–98 (14).
Thygesen K, Alpert JS, Jaffe AS, et al.





In the patient with a presumed acute STEMI, the
angiographic appearance of thrombus (typically a ﬁlling
defect) on angiography. This includes the aspiration of
thrombus from the infarct vessel before coronary
intervention during primary PCI for acute STEMI.
Thrombus at autopsy Identiﬁcation of thrombus in a major epicardial vessel at
autopsy.

















































Terminology Concept Concept Deﬁnition
Suggested Data
Element Label Permissible Values Permissible Value Deﬁnitions Citations and References
Acute MI—Change in
Noninvasive Imaging
Demonstration of a new
change in myocardial viability
or function consistent with
MI. This is one of the
noncardiac marker criteria
supporting the diagnosis of




 New loss of viable
myocardium
 New regional wall
motion abnormality
Thygesen K, Alpert JS, Jaffe AS, et al.
Third universal deﬁnition of myocardial
infarction. J Am Coll Cardiol.
2012;60:1581–98 (14).
Thygesen K, Alpert JS, Jaffe AS, et al.
Third universal deﬁnition of myocardial
infarction. Circulation. 2012;126:2020–
35 (13).
New loss of viable
myocardium
Noninvasive imaging evidence of a loss of viable myocardium
when compared with the most recent previous noninvasive
imaging study.
New regional wall motion
abnormality
Noninvasive imaging evidence of a decrease in regional wall





Occurrence of an adverse
angiographic ﬁnding during
PCI consistent with acute
myocardial ischemia. This is
one of the noncardiac marker
criteria supporting the




 Loss of major
coronary
 Loss of side branch
 Slow ﬂow/no ﬂow/
embolization
Thygesen K, Alpert JS, Jaffe AS, et al.
Third universal deﬁnition of myocardial
infarction. J Am Coll Cardiol.
2012;60:1581–98 (14).
Thygesen K, Alpert JS, Jaffe AS, et al.
Third universal deﬁnition of myocardial
infarction. Circulation. 2012;126:2020–
35 (13).
Loss of major coronary Angiographic loss of patency of a major epicardial vessel.
Loss of side branch Angiographic loss of patency of a side branch.
Slow ﬂow/no ﬂow/
embolization





of a new CABG or new native
coronary artery occlusion
within 48 h of CABG surgery.
This is one of the noncardiac
marker criteria supporting the







Thygesen K, Alpert JS, Jaffe AS, et al.
Third universal deﬁnition of myocardial
infarction. J Am Coll Cardiol.
2012;60:1581–98 (14).
Thygesen K, Alpert JS, Jaffe AS, et al.
Third universal deﬁnition of myocardial
infarction. Circulation. 2012;126:2020–
35 (13).
Continued on the next page














































Terminology Concept Concept Deﬁnition
Suggested Data
Element Label Permissible Values Permissible Value Deﬁnitions Citations and References
Prior MI Presence of any one of the
following criteria meets the
diagnosis for prior MI (before
study initiation):
a) Pathological Q waves
with or without symp-
toms in the absence of
nonischemic causes
b) Imaging evidence of a
region of loss of viable
myocardium that is thin-
ned and/or fails to con-
tract, in the absence of a
nonischemic cause






Thygesen K, Alpert JS, Jaffe AS, et al.
Third universal deﬁnition of myocardial
infarction. J Am Coll Cardiol.
2012;60:1581–98 (14).
Thygesen K, Alpert JS, Jaffe AS, et al.
Third universal deﬁnition of myocardial
infarction. Circulation. 2012;126:2020–
35 (13).
Cardiac Biomarker—Name Name of cardiac biomarker
test, per LOINC nomenclature.
Cardiac Biomarker
Test
 LOINC Test Name LOINC. Available at www.loinc.org
(50).
Cardiac Biomarker—Value Serum concentration result of




Cardiac Biomarker—Unit Unit of measure of the result
of a cardiac biomarker test.
Cardiac Biomarker
Unit







Date and time a specimen was














Unit of measure of the 99%
URL of a cardiac biomarker.
Cardiac Biomarker
99% URL Unit





















ACC indicates American College of Cardiology; ACCF, American College of Cardiology Foundation; AHA, American Heart Association; CABG, coronary artery bypass graft; CAD, coronary artery disease; CK-MB, creatinine kinase MB; cTn, cardiac troponin;
ECG, electrocardiogram; ESC, European Society of Cardiology; HF, heart failure; ICD, implantable cardioverter-deﬁbrillator; LBBB, left bundle-branch block; LOINC, Logical Observation Identiﬁers Names and Codes; LVH, left ventricular hypertrophy;
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occurring within 24 h
of the most recent
symptoms.
Hospitalization is deﬁned
as an admission to an
inpatient unit or a visit to
an ED that results in at
least a 24-h stay (or a
change in calendar date if
the hospital admission or
discharge times are not
available).
This classiﬁcation requires














evidence, is not sufﬁcient




UA does not qualify as a
UA hospitalization if a
noncardiac or non-
ischemic etiology is sub-
sequently identiﬁed.
An ischemic event
meeting the criteria for




formance of an elective
revascularization proce-
dure (e.g., positive stress
test, staged revasculari-









































Date and time of the
presentation of the
patient to the hospital for
management of UA.
Date and time of
presentation is deﬁned as
the date and time of
registration in the ED (or
hospital, if the patient is
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equivalent) $10 min in
duration occurring either
a) At rest, or



























































New or worsening ST
or T-wave changes on
resting ECG (in the
absence of confounders,
such as LBBB or LVH),
deﬁned as either
a) Transient ST elevation
(duration <20 min):
new ST elevation at the
J point $0.1 mV in any
2 contiguous leads
(other than leads V2
to V3); in leads V2 to V3,
the following cut
points apply: $0.2 mV
in men $40 y of
age, $0.25 mV in
men <40 y of age,
and $0.15 mV in
women.






leads and/or new T
inversion $0.3 mV in
2 contiguous leads with
prominent R wave or
R/S ratio >1.
Continued on the next page




















a) An early positive
exercise stress test
result, deﬁned as

















of new or worsening
lesion $70% ($50% for
left main coronary artery
lesion) and/or thrombus in
an epicardial coronary




Coronary revascularization Need for coronary
revascularization procedure
(PCI or CABG) for the
presumed culprit lesion(s).











Exclusion of the diagnosis
of MI as the reason for
hospitalization, including
negative cardiac
biomarkers and no other





ACCF indicates American College of Cardiology Foundation; AHA, American Heart Association; CABG, coronary artery bypass graft; CAD, coronary artery disease; ECG, electrocar-
diogram; ED, emergency department; LBBB, left bundle-branch block; LVH, left ventricular hypertrophy; METs, metabolic equivalents; MI, myocardial infarction, MRI, magnetic
resonance imaging; PCI, percutaneous coronary intervention; and UA, unstable angina.
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Stroke An acute episode of focal
or global neurological
dysfunction caused by brain,
spinal cord, or retinal vascular
injury as a result of
hemorrhage or infarction.
Stroke Indicator  Yes
 No
Adapted from Sacco RL,
Kasner SE, Broderick JP, et al.
An updated deﬁnition of







Stroke—Date–Time Date and time of the onset of
a stroke.
Stroke Date_Time  Date–time
Stroke—Type Categorical description of
stroke type, classiﬁed into
1 of 3 mutually exclusive
categories (ischemic,
hemorrhagic, undetermined).
Stroke Type  Ischemic
 Hemorrhagic
 Undetermined
Adapted from Sacco RL,
Kasner SE, Broderick JP, et al.
An updated deﬁnition of







Ischemic An acute episode of focal
cerebral, spinal, or retinal
dysfunction caused by
infarction of central nervous
system tissue.
Note: Hemorrhage may be a
consequence of ischemic
stroke. In this situation, the
stroke is an ischemic stroke
with hemorrhagic
transformation and not a
hemorrhagic stroke.
Hemorrhagic Hemorrhagic: An acute
episode of focal or global






events and not strokes.
Undetermined Undetermined: An acute
episode of focal or global
neurological dysfunction
caused by presumed brain,
spinal cord, or retinal vascular
injury as a result of
hemorrhage or infarction but
with insufﬁcient information








Note: Measure disability with
the modiﬁed Rankin Scale at











Rankin J. Cerebral vascular
accidents in patients over the
age of 60. Scott Med J.
1957;2:200–15 (26).
van Swieten J, Koudstaal P,
Visser M, et al. Interobserver
agreement for the assessment
of handicap in stroke patients.
Stroke. 1988;19:604–7 (51).











0 No symptoms at all.
1 No signiﬁcant disability
despite symptoms; able to
carry out all usual duties and
activities.
2 Slight disability; unable to
perform all previous activities
but able to look after own
affairs without assistance.
3 Moderate disability; requiring
some help but able to walk
without assistance.
4 Moderately severe disability;
unable to walk without
assistance and unable to
attend to own bodily needs
without assistance.
5 Severe disability; bedridden,
incontinent, and requiring






Date and time of neurological
assessment to determine
modiﬁed Rankin scale grade.
Rankin Scale Date_Time Date–time
TIA Transient episode of focal
neurological dysfunction
caused by brain, spinal cord,
or retinal ischemia without
acute infarction.
Note: Persistence of
symptoms is an acceptable
indicator of acute infarction. If
it is used, duration of
symptom persistence that will
be used to distinguish
between transient ischemia
and acute infarction should be
deﬁned for any clinical trial in
which it is used.
Note: AHA/ASA recommends
duration $24 h as an
operational deﬁnition of
persisting symptoms of stroke
rather than TIA, based mostly






Easton JD, Saver JL, Albers
GW, et al. Deﬁnition and
evaluation of transient















Sacco RL, Kasner SE,
Broderick JP, et al. An
updated deﬁnition of stroke












AHA indicates American Heart Association; ASA, American Stroke Association; and TIA, transient ischemic attack.
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HF Event Presentation of the patient
for an urgent, unscheduled
clinic/ofﬁce/ED visit or
hospital admission, with a
primary diagnosis of HF,
where the patient exhibits
new or worsening
symptoms of HF on
presentation, has objective
evidence of new or





of at least 2 physical
examination ﬁndings OR at
least 1 physical examination
ﬁnding and at least 1
laboratory criterion of new








HF Event—Date–Time Date and time of the
presentation of a patient








The type of healthcare
encounter of a patient








 Urgent HF visit
http://www.cdisc.org/
therapeutic (49)
HF hospitalization An event where the
patient is admitted to the
hospital with a primary
diagnosis of HF where the
length of stay is at least
24 h (or extends over a




patient exhibits new or
worsening symptoms of
HF on presentation, has
objective evidence of new





Urgent HF visit An event where the
patient has an urgent,
unscheduled ofﬁce/
practice/ED visit for a
primary diagnosis of HF
but is not admitted to the
hospital, where the patient
exhibits new or worsening
symptoms of HF on
presentation, has objective





HF, with the exception
that changes to oral
diuretic therapy do not
qualify as initiation or
intensiﬁcation of
treatment.
Continued on the next page











Documentation of new or
worsening symptoms of HF
on patient presentation.
Criterion for new or
worsening symptoms due to




















MJ, Arnold JM, Bennett




and outcomes of patients
with chronic heart


















Dyspnea Includes dyspnea on








to withstand or participate
in activities that induce
physical or mental
exertion.
Fatigue Unusual tiredness and




Decreased blood supply to
the vital organs (kidney,
liver, lungs, heart, and
brain).
Note: Parameters must be
speciﬁed and described by
the study protocol.





Note: Parameters must be





Documentation of new or
worsening physical
examination ﬁndings of HF
on patient presentation.
Criterion for new or
worsening objective
ﬁndings due to HF includes
at least 2 physical
examination ﬁndings OR 1
physical examination
ﬁnding and at least 1
laboratory criterion.
Physical examination
















or rapid weight gain
Adapted from Radford
MJ, Arnold JM, Bennett




and outcomes of patients
with chronic heart




Force on Clinical Data
Standards (Writing
Committee to Develop
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f) Clinically signiﬁcant or
rapid weight gain













Peripheral edema Increased tissue ﬂuid
indicated by perceptible
pitting indentation on














breath sounds caused by





Increase in the estimated
height of the mean jugular
venous waveform above
the right atrium in
centimeters.




recorded as written. When
it is expressed as
centimeters above the
sternal angle, 5 cm should
be added to the number
recorded. In the absence
of a numerical estimate of
jugular venous pressure,
“JVD,” “distended neck
veins,” and “halfway to the
jaw” or “to the angle of
the jaw” would be
recorded as positive for
elevated jugular venous
pressure.
S3 gallop Presence of an S3 mid-
diastolic heart sound.
Clinically signiﬁcant
or rapid weight gain
Weight gain thought to be




Documentation of new or
worsening laboratory
evidence of HF obtained
within 24 h of patient
presentation.
Criterion for new or
worsening objective
ﬁndings due to HF includes
at least 2 physical
examination ﬁndings OR 1
physical examination

















MJ, Arnold JM, Bennett




and outcomes of patients
with chronic heart




Force on Clinical Data
Standards (Writing
Committee to Develop
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Increase in HF biomarker Biomarker increase BNP/
NT-pro BNP with
decompensation of HF
(such as BNP >500 pg/mL
or NT-proBNP >2,000

















































for HF. The criterion is that
the patient receives initiation
or intensiﬁcation of
treatment speciﬁcally for
HF, including at least 1
of the following:
a) Augmentation in oral
diuretic therapy













 Mechanical or surgi-
cal intervention
Adapted from Radford
MJ, Arnold JM, Bennett




and outcomes of patients
with chronic heart
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Cardiogenic Shock Sustained (>30 min)
episode of systolic
BP <90 mmHg and/or
cardiac index <2.2 L/min/










device) to maintain BP and






Cannon CP, Brindis RG,
Chaitman BR, et al.
2013 ACCF/AHA key data
elements and deﬁnitions





artery disease: a report










Data Standards). J Am
Coll Cardiol.
2013;61:992–1025 (16).
ACCF indicates American College of Cardiology Foundation; AHA, American Heart Association; BNP, B-type natriuretic peptide; BP, blood pressure; cm, centimeter; ED, emergency
department; HF, heart failure; JVD, jugular venous distention; L/min/m2, liter per minute per square millimeter; LVOT, left ventricular outﬂow tract; mmHg, millimeters of mercury;
NT-pro BNP, N-terminal pro B-type natriuretic peptide; PCWP, pulmonary capillary wedge pressure; and TVI, time velocity integral.
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 A Heart Failure Event includes hospitalization for HF and may include urgent, unscheduled outpatient ofﬁce/practice or ED visits.
– A Heart Failure Hospitalization is deﬁned as an event in which the patient is admitted to the hospital with a primary diagnosis of HF, the length of stay is
at least 24 h (or extends over a calendar date), the patient exhibits new or worsening symptoms of HF on presentation, has objective evidence of new or
worsening HF, and receives initiation or intensiﬁcation of treatment speciﬁcally for HF.
– An Urgent Heart Failure Visit is deﬁned as an event in which the patient has an urgent, unscheduled ofﬁce/practice or ED visit for a primary diagnosis of
HF but is not admitted to the hospital and exhibits new or worsening symptoms of HF on presentation, has objective evidence of new or worsening HF,
and receives initiation or intensiﬁcation of treatment speciﬁcally for HF. Note that changes to oral diuretic therapy do not qualify as initiation or
intensiﬁcation of treatment.
 Heart Failure Symptoms: The patient may present with new or worsening symptoms due to HF on presentation. To be deﬁned as having new or worsening
symptoms due to HF, the patient should have at least at least 1 of the following on presentation:
– Dyspnea (dyspnea with exertion, dyspnea at rest, orthopnea, paroxysmal nocturnal dyspnea, nocturnal cough in supine position, tachypnea);
– Decreased exercise tolerance (reduced ability to perform activities that involve dynamic movement of large skeletal muscles because of symptoms of
dyspnea or fatigue);
– Fatigue (usually described as feeling a lack of energy and motivation in both mental and physical activities, easily tiring and not being able to complete
usual activities, and sometimes accompanied by dizziness, lightheadedness);
– Worsened end-organ perfusion (worsening cerebral, renal, liver, abdominal or gastrointestinal, peripheral circulatory function manifested by symptoms
such as dizziness, lightheadedness, syncope, confusion, altered mental status, restlessness, decline in cognitive state, nausea, vomiting, abdominal pain,
abdominal fullness, abdominal discomfort or abdominal tenderness, cold clammy extremities, discoloration of extremities or lips, jaundice, pain in
extremities, reduced urine output, darkening of urine color, chest pain, and/or palpitations); or
– Other symptoms of volume overload (swelling of lower extremities; swelling or indentation of pressure marks in areas of ﬂuid accumulation such as the
legs, ankles, or lower back; an increase in abdominal girth, right-sided abdominal fullness, discomfort, or tenderness; an increase in body weight; oozing
and development of skin breakdown in lower extremities).
 Heart Failure Signs: The patient may present with objective evidence of new or worsening HF. The objective evidence or signs of new or worsening HF
should consist of at least 2 physical examination ﬁndings OR 1 physical examination ﬁnding and at least 1 laboratory criterion. Physical examination ﬁndings
considered to be due to HF include new or worsened:
– Peripheral edema (swelling or pitting indentation when pressed in feet, ankles, legs, thighs, upper extremities, scrotum, presacral area, or abdominal
wall).
– Increasing abdominal distention or ascites (in the absence of primary hepatic disease)
– Pulmonary rales/crackles/crepitations
– Increased jugular venous pressure and/or hepatojugular reﬂux
– S3 gallop
– Clinically signiﬁcant or rapid weight gain thought to be related to ﬂuid retention (usually >3–4 lb in 3–4 d).
Other physical ﬁndings such as the following may also support the diagnosis: a decline in systolic or diastolic blood pressure; orthostatic hypotension; cool,
mottled or clammy skin; lip discoloration and cyanosis; tachypnea; irregular or periodic breathing pattern (e.g., Cheyne-Stokes respirations); tachycardia or
bradycardia; arrhythmia; irregular pulse; pulsus alternans; displaced point of maximum impulse of cardiac apex; RV heave; loud S2; diminished S1; S4;
valvular murmurs; reduced urine output; liver enlargement; physical ﬁndings compatible with pleural effusion such as decreased breath sounds and or
decreased egophony; narrow pulse pressure; abnormal arterial pulse pressure response during the strain phase of the Valsalva maneuver; weight loss;
and/or wheezing (29,32,33). Because these physical ﬁndings are not as common, sensitive, speciﬁc, or easily reproducible for HF as those listed in the bullet
points above, they are not included in the required physical ﬁndings criteria.
 Laboratory Evidence of HF: Laboratory evidence of new or worsening HF should be obtained within 24 h of presentation.
Laboratory criteria include new or worsened:
– Increased BNP or NT-proBNP concentrations. In patients with suspected new onset of HF, or in patients with dyspnea but uncertainty of HF,
measurement of BNP or NT-proBNP is useful to support the clinical diagnosis of HF (30,31,35,39,40). In acute decompensated HF, natriuretic peptide
levels are usually signiﬁcantly elevated (e.g., BNP >500 pg/mL or NT-proBNP >2,000 pg/mL). The exclusion threshold differs for patients presenting
with acute onset or worsening of symptoms and for those presenting with more gradual onset of symptoms. For patients presenting with acute onset or
worsening of symptoms, the optimal exclusion cut-off points are usually quoted as 300 pg/mL for NT-proBNP and 100 pg/mL for BNP levels. Lower
values of natriuretic peptides usually make the diagnosis of HF less likely, and higher values have reasonably high positive predictive value in diagnosing
HF, especially in dyspneic patients presenting to urgent care or ED settings. That being said, elevated plasma levels of natriuretic peptides can be seen
with a variety of other cardiac and noncardiac causes. Other causes of elevated natriuretic peptide levels in the acute setting are acute coronary
syndrome, atrial or ventricular arrhythmias, pulmonary embolism, cor pulmonale, renal failure, and sepsis. Other causes of an elevated natriuretic level in
the nonacute setting are old age (>75 y), atrial arrhythmias, LV hypertrophy, chronic obstructive pulmonary disease, and chronic kidney disease.
Conversely, natriuretic peptide levels can be lower in obese patients. In patients with chronically elevated natriuretic peptides, levels usually correlate
with HF severity and prognosis, and an increase above the baseline is usually noted during acute decompensated HF. Current evidence suggests there is
no speciﬁc cut-off point for an absolute or relative rise above the baseline level to diagnose a HF event in patients with chronically elevated natriuretic
peptide levels.
– Radiological evidence of pulmonary congestion (CXR or other imaging modality such as CT or MRI with evidence of pulmonary venous or alveolar
congestion, interstitial or pulmonary edema, pleural effusion, or cephalization of venous ﬂow. It is important to note that CXR may also reﬂect evidence
of cardiomegaly.)
– Noninvasive diagnostic evidence of HF (echocardiography, cardiac MRI, cardiac PET scan, and nuclear imaging) can provide information about cardiac
anatomy such as LV or RV function, volumes, geometry, wall motion, or valvular function, and other ﬁndings such as elevated ﬁlling pressures by Doppler
echocardiography) supporting the diagnosis and etiology of HF. In systolic HF, LV ejection fraction (<50%) and LV fractional shortening are reduced
(<25%). There may be regional LV wall motion abnormalities, especially in patients with ischemic HF. In patients with chronic systolic HF, LV end-
diastolic size is usually increased (diameter $60 mm, >32 mm/m2, LV volume >97 mL/m2), as is LV end-systolic size (diameter >45 mm/>25 mm/m2,
volume >43 mL/m2). Cardiac output is usually reduced, and LV outﬂow tract velocity time integral is reduced (<15 cm). LV diastolic dysfunction
parameters may reﬂect abnormalities of the mitral inﬂow pattern, with tissue velocities (e) or the E/e’ ratio indicating the presence and degree of LV
diastolic dysfunction. In cases of diastolic dysfunction, e’ is decreased (<8 cm/s septal, <10 cm/s lateral, or <9 cm/s average), suggesting delayed LV
relaxation. High E/e’ ratios (>15) usually indicate high LV ﬁlling pressures, whereas low E/e’ ratios (<8) usually indicate normal LV ﬁlling pressures. A
mitral inﬂow E/A ratio >2 suggests restrictive, high LV ﬁlling pressures. In contrast, a mitral inﬂow E/A ratio of <1 suggests delayed LV relaxation with
normal LV ﬁlling pressures. An E/A ratio of 1–2 may be inconclusive or pseudonormal. Mitral inﬂow during the Valsalva maneuver may reﬂect a change
from the pseudonormal to the impaired relaxation pattern (with a decrease in E/A ratio >0.5), suggesting high LV ﬁlling pressures (unmasked through
Valsalva). An A-wave duration >30 ms usually suggests high LV ﬁlling pressures. In patients with elevated ﬁlling pressures, left atrial volume index is
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usually increased (volume >34 mL/m2) (34,38,39) In HF, LV mass index is usually increased to >95 g/m2 in women and >115 g/m2 in men. Valvular
structure and function may reveal valvular stenosis or regurgitation, especially aortic stenosis and mitral regurgitation, and may be the cause, result, or a
complicating factor of HF (secondary mitral regurgitation). RV function (e.g., TAPSE) may be reduced (TAPSE <16 mm). Tricuspid regurgitation peak
velocity may be increased (>3.4 m/s), suggesting increased RV systolic pressures. Systolic pulmonary artery pressure may be increased (>50 mmHg)
with pulmonary hypertension. The inferior vena cava may be dilated, with no respiratory collapse, suggesting increased right atrial pressures, RV
dysfunction, volume overload, or pulmonary hypertension.
– Invasive diagnostic evidence of HF (right-sided heart catheterization) may reveal elevated PCWP, reduced cardiac output or cardiac index, elevated right
atrial pressure, or reduced mixed venous oxygen saturation. Left-sided heart catheterization may reveal elevated LVEDP. In patients with LV failure,
PCWP or LVEDP is usually elevated over 18 mmHg. In patients with decompensated HF, right atrial pressure or central venous pressure is usually >12
mmHg, and cardiac index is usually <2.2 L/min/m2 (28).
All results from diagnostic tests should be reported if available, even if they do not meet the above criteria, because they provide important information for
the adjudication of these events.
 Initiation or Intensiﬁcation of HF Treatment: The criterion is that the patient receives initiation or intensiﬁcation of treatment speciﬁcally for HF, including
at least 1 of the following:
1) Augmentation in oral diuretic therapy (increase in oral diuretic dose or addition of another oral diuretic)
2) Intravenous diuretic or intravenous vasoactive therapy. Vasoactive therapy may include an intravenous inotrope, vasodilator, or vasopressor.
3) Mechanical or surgical intervention, including:
 Mechanical circulatory support (e.g., intra-aortic balloon pump, ventricular assist device, extracorporeal membrane oxygenation, total artiﬁcial heart)
 Mechanical ﬂuid removal (e.g., ultraﬁltration, hemoﬁltration, dialysis)
BNP indicates B-type natriuretic peptide; CT, computed tomography; CXR, chest X-ray; ED, emergency department; HF, heart failure; LV, left ventricular; LVEDP, left ventricular end-
diastolic pressure; MRI, magnetic resonance imaging; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PCWP, pulmonary capillary wedge pressure; PET, positron emission
tomography; RV, right ventricular; and TAPSE, Tricuspid Annular Plane Systolic Excursion.
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PCI PCI is the placement of
an angioplasty
guidewire, balloon, or




catheter) into a native
coronary artery or CABG




























PCI—Status Classiﬁcation of the
urgency of a PCI
procedure at the time





































Urgent A procedure that should








outpatients or in the ED
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Emergency A procedure that should





could lead to death. “As
soon as possible” refers
to a patient whose
condition is sufﬁciently
acute that the provider
would 1) cancel a
scheduled case to
perform the procedure
immediately in the next
available room during
business hours or 2)
would activate the on-
call team if this were to
occur during off-hours.
Salvage A procedure that is a last
resort. The patient is in
cardiogenic shock when
the PCI begins (i.e., the





bypass graft for the
purpose of mechanical
revascularization) or
within the last 10 min
before the start of the
case; or during the
diagnostic portion of the
case, the patient
received chest








PCI—Procedure Success Achievement of <30%
residual diameter
stenosis of all treated
lesions as assessed by
visual inspection or
QCA, without an in-
hospital major adverse
cardiac event (death,
MI, or repeat coronary
revascularization of the
target lesion).














Levine GN, Bates ER,




intervention. A report of
the American College of
Cardiology Foundation/
American Heart
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Name of the coronary
artery segment where
PCI was performed that




treated or for which
treatment was
attempted with a device
or technique being
studied. The length of
the target lesion is
inclusive of the arterial
section treated with the
study device (e.g., a
stent) and the 5 mm
proximal and 5 mm



















stenosis of the target
lesion as assessed by
visual inspection or
QCA, without an in-
hospital major adverse
cardiac event (death,
MI, or repeat coronary
revascularization of the










In the context of clinical
investigation, ideally
the assessment of the
residual stenosis at the
end of the procedure









Adapted from Levine GN,
Bates ER, Blankenship JC,
et al. 2011 ACCF/AHA/
SCAI guideline for
percutaneous coronary
intervention. A report of
the American College of
Cardiology Foundation/
American Heart








PCI—Abrupt Closure New intraprocedural
severely reduced ﬂow
(TIMI grade 0–1) within
the target vessel that
persists and requires
intervention by stenting
or other treatment or
results in MI or death.
Abrupt closure requires
an association with a
vascular dissection,
thrombus, or severe
spasm at the treatment







SM, ed. Complications of
Percutaneous Coronary
Interventions. New York,
NY: Springer; 2010 (55).
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dimensions of a lesion
and/or vessel.
 Grade F transluminal coronary
angioplasty. In: Manual of
Operations: NHLBI PTCA
Registry. Bethesda, MD:
National Heart, Lung, and
Blood Institute; 1985:6–9
(56).
Grade A Minor radiolucencies
within the lumen during
contrast injection with
no persistence after dye
clearance.
Grade B Parallel tracts or double
lumen separated by a
radiolucent area during
contrast injection with
no persistence after dye
clearance.
Grade C Extraluminal cap with
persistence of contrast
after dye clearance from
the lumen.
Grade D Spiral luminal ﬁlling
defect with delayed but
complete distal ﬂow.




Grade F Non–A-E types with
total coronary occlusion
and no distal antegrade
ﬂow. May represent
thrombus.
PCI—No Reﬂow New acute reduction in
coronary ﬂow (TIMI











SM, ed. Complications of
Percutaneous Coronary
Interventions. New York,




of compromise of a PCI
vessel by coronary
artery thrombus (blood
clot) occurring at any
time during a procedure
and independent of












c) No reﬂow (from
TIMI ﬂow 3/2 to 1/
0) or slow reﬂow








SM, ed. Complications of
Percutaneous Coronary
Interventions. New York,
NY: Springer; 2010 (55).
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Occlusion of the lumen
of a newly implanted
stent by thrombus








SM, ed. Complications of
Percutaneous Coronary
Interventions. New York,
NY: Springer; 2010 (55).
PCI—Stent Thrombosis Compromise of the
lumen of a coronary
stent by thrombus
(blood clot) and not as a
result of restenosis or
atherosclerosis after





















thrombus is deﬁned as
the presence of TIMI
0 or TIMI 1 ﬂow
intrastent or proximal
to a stent up to the
most adjacent proximal
side branch or main
branch (if it originates















Cutlip DE, Windecker S,
Mehran R, et al. Clinical
endpoints in coronary






















occlusion in the absence










Cutlip DE, Windecker S,
Mehran R, et al. Clinical
endpoints in coronary
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presence of a thrombus
at coronary angiography
that originates in the
stent or in the segment
5 mm proximal or distal
to the stent, with the
presence of at least 1 of
3 clinical criteria within a
48-h time window:



































b) irrespective of the
time after the index
procedure, any MI
that is related to
documented acute







the absence of any
other obvious
cause.
Possible Possible: Possible stent
thrombosis is considered
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Timing of the detection
of stent thrombosis
according to the ARC
grading criteria, with
time 0 deﬁned as the
time when the patient
departs the
catheterization
laboratory after a stent
implantation procedure.
Note: The combination
of acute or subacute
stent thrombosis can be









Cutlip DE, Windecker S,
Mehran R, et al. Clinical
endpoints in coronary




Acute 0–24 h after stent
implantation
Subacute >24 h to 30 d after
stent implantation
Late >30 d to 1 y after stent
implantation
Very late >1 y after stent
implantation
PCI—Stent Restenosis Renarrowing of a stent
implanted at a lesion
site to treat a prior
stenosis, to a diameter
stenosis of >50%
within the stent,
inclusive of the original
treated site plus the
adjacent vascular
segments 5 mm
proximal and 5 mm







Adapted from Levine GN,
Bates ER, Blankenship JC,
et al. 2011 ACCF/AHA/
SCAI guideline for
percutaneous coronary
intervention. A report of
the American College of
Cardiology Foundation/
American Heart








PCI—Lesion Restenosis Renarrowing of a lesion
site following treatment
of a prior stenosis, to a
diameter stenosis of
>50% at the previously
treated lesion site,
inclusive of the original
treated site plus the
adjacent vascular
segments 5 mm
proximal and 5 mm








Adapted from Levine GN,
Bates ER, Blankenship JC,
et al. 2011 ACCF/AHA/
SCAI guideline for
percutaneous coronary
intervention. A report of
the American College of
Cardiology Foundation/
American Heart









intervention of a target
lesion, or surgical










Cutlip DE, Windecker S,
Mehran R, et al. Clinical
endpoints in coronary
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the target lesion. The
length of the target
lesion is inclusive of the
treated section and the
5 mm proximal and
distal to the treated
section.
In the assessment of
TLR, angiograms should




available to the CEC for
review on request.
PCI—Ischemia Before TLR Criteria for clinical or
functional ischemia
include any of the
following:
a) History of angina
pectoris, presum-
ably related to the
target vessel







to the target vessel
c) Abnormal results of
any invasive func-
tional diagnostic








Cutlip DE, Windecker S,
Mehran R, et al. Clinical
endpoints in coronary




PCI—Clinically Driven TLR PCI–TLR is clinically
driven if the target
lesion diameter stenosis
is >50% by QCA and





bypass graft lesion. TLR
of a >70% diameter
stenosis by QCA in the
absence of the above
signs or symptoms may
be considered clinically
driven. In the absence
of QCA data or if a
stenosis #50% is
present, TLR may be
considered clinically
driven if severe ischemic
signs and symptoms








Cutlip DE, Windecker S,
Mehran R, et al. Clinical
endpoints in coronary




PCI—TLF The composite of
ischemia-driven target
lesion revascularization,
MI related to the target
vessel, or cardiac death
related to the target
vessel. If it cannot be
determined with
certainty whether an MI
or death was related to







Cutlip DE, Windecker S,
Mehran R, et al. Clinical
endpoints in coronary
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PCI—Target Vessel In the context of clinical
investigation, the major
native coronary artery
(e.g., left main coronary
artery, LAD coronary
artery, left circumﬂex
coronary artery, or right
coronary artery) or
bypass graft containing











 Left main artery
 LAD artery
 Left circumﬂex artery
 Ramus intermedius
artery









Left main artery Left main coronary
artery.
SNOMED-CT: 3227004















Ramus intermedius artery Ramus intermedius
coronary branch.
SNOMED-CT: 244252004
Right coronary artery Right coronary artery










PCI—TVR Repeat PCI or surgical
bypass of any segment
of a coronary artery
containing a target
lesion. A target vessel is
deﬁned as the entire
major coronary vessel




and the target lesion
itself.
In the assessment of
TVR, angiograms should












Cutlip DE, Windecker S,
Mehran R, et al. Clinical
endpoints in coronary
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PCI—TVF The composite of
ischemia-driven TVR, MI
related to the target
vessel, or cardiac death
related to the target
vessel. If it cannot be
determined with
certainty whether the
MI or death was related







Cutlip DE, Windecker S,
Mehran R, et al. Clinical
endpoints in coronary






Name of a coronary
artery segment where
PCI was performed that
is NOT the subject of
clinical investigation. In
the context of clinical
investigation, any lesion
not treated or for which
no attempt at treatment























Any (de novo or repeat)
PCI of a nontarget
lesion or surgical bypass
of a nontarget vessel.
This includes
revascularization at the
time of an index (study)
PCI of a separate target
lesion and subsequent
revascularization after







Cutlip DE, Windecker S,
Mehran R, et al. Clinical
endpoints in coronary




PCI—Nontarget Vessel In the context of clinical
investigation, any major
native coronary artery
(e.g., left main coronary
artery, LAD coronary
artery, left circumﬂex
coronary artery, or right
coronary artery) or
bypass graft not treated
or for which no attempt
at treatment was made










 Left main artery
 LAD artery
 Left circumﬂex artery
 Ramus intermedius
artery









Left main artery Left main coronary
artery.
SNOMED-CT: 3227004
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Ramus intermedius artery Ramus intermedius
coronary branch.
SNOMED-CT: 244252004
Right coronary artery Right coronary artery












Any (de novo or repeat)
PCI or surgical bypass of




time of an index (study)
PCI of a separate target
lesion and subsequent
revascularization after







Cutlip DE, Windecker S,
Mehran R, et al. Clinical
endpoints in coronary












described by the TIMI
Group.




Cannon CP, Brindis RG,
Chaitman BR, et al. 2013
ACCF/AHA key data
elements and deﬁnitions
for measuring the clinical
management and
outcomes of patients with
acute coronary
syndromes and coronary
artery disease. A report of
the American College of
Cardiology Foundation/
American Heart






Data Standards). J Am
Coll Cardiol.
2013;61:992–1025 (16).
Grade 0 No perfusion. There is
no antegrade ﬂow
beyond the point of
occlusion.
Grade 1 Penetration without
perfusion. Contrast
material passes beyond
the area of obstruction
but “hangs up” and fails
to opacify the entire
coronary bed distal to
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coronary bed distal to
the obstruction.
However, the rate of
entry of contrast
material into the vessel
distal to the obstruction
or its rate of clearance
from the distal bed (or
both) is perceptibly
slower than its entry






or the coronary bed
proximal to the
obstruction).
Grade 3 Complete perfusion.
Antegrade ﬂow into the
bed distal to the
obstruction occurs as





involved bed is as rapid
as from an uninvolved
bed in the same vessel














Adapted from Capone G,
Wolf NM, Meyer B,
Meister SG. Frequency of
intracoronary ﬁlling
defects by angiography in



















Cannon CP, Braunwald E,
McCabe CH, et al.
The Thrombolysis in
Myocardial Infarction
trials: the ﬁrst decade.
J Interv Cardiol. 1995;
8:117–35 (58).







or a smooth convex




Grade 2 Small deﬁnite thrombus,
with the greatest
dimension less than or
equal to one-half of the
vessel diameter.
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one-half but <2 vessel
diameters.









Development of a new,
localized collection of
blood at a vascular
access site sufﬁcient to
produce a palpable







SM, ed. Complications of
Percutaneous Coronary
Interventions. New York,




Development of a new,
unintended
communication
between an artery and a
vein occurring at a
vascular access site







SM, ed. Complications of
Percutaneous Coronary
Interventions. New York,










paresthesia) distal to a
vascular access site







SM, ed. Complications of
Percutaneous Coronary
Interventions. New York,














nerve damage from the
procedure, occurring







SM, ed. Complications of
Percutaneous Coronary
Interventions. New York,




Development of a new
localized collection of
blood with a persistent
communication (neck)
originating at a vascular
access site and







SM, ed. Complications of
Percutaneous Coronary
Interventions. New York,








originating at a vascular
access site and







SM, ed. Complications of
Percutaneous Coronary
Interventions. New York,
NY: Springer; 2010 (55).
Continued on the next page
APPENDIX 9. CONTINUED
Hicks et al. J A C C V O L . 6 6 , N O . 4 , 2 0 1 5
Cardiovascular Endpoints Data Standards J U L Y 2 8 , 2 0 1 5 : 4 0 3 – 6 9
452









CABG CABG surgery is a
procedure performed





elsewhere in the body,
thereby improving the









CABG—Status Classiﬁcation of the
urgency of a CABG
surgical procedure,










Elective Patient cardiac status
has been stable in the














include (but are not
limited to) acute or
worsening chest pain,




















one in which there
should be no delay in
providing operative
intervention. The clinical
status of the patient can
include any of the
following:
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within 24 h before






of the following): 1)
shock with circula-
tory support or 2)
shock without cir-
culatory support.
Salvage The patient is







































CABG—Type Type of CABG conduit. Coronary Artery Graft
Type
 Saphenous vein graft
 Arterial graft, in situ
 Arterial graft, free
Saphenous vein graft CABG composed of
saphenous vein.
Arterial graft, in situ CABG composed of
arterial conduit, where
the origin of the graft
remains intact.
Arterial graft, free CABG composed of
an artery that has
been completely
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Graft origin The section of a graft
from the connection
(anastomosis) of the
graft with the aorta (or
from the origin if in situ),
inclusive of the ﬁrst 3
mm of the graft.
Graft body The section of a graft
between the origin and
the anastomosis.
Graft anastomosis The section of a graft
from the connection
(anastomosis) of the
graft with the coronary
artery, inclusive of the
retrograde 3 mm of the
graft.
CABG—Anastomosis The coronary artery







ACCF indicates American College of Cardiology Foundation; AHA, American Heart Association; ARC, Academic Research Consortium; CABG, coronary artery bypass graft; CEC, Clinical
Events Committee; CFR, coronary ﬂow reserve; CPR, cardiopulmonary resuscitation; ECG, electrocardiogram; ED, emergency department; FFR, fractional ﬂow reserve; IABP, intra-
aortic balloon bump; LAD, left anterior descending; MI, myocardial infarction; mm, millimeter; NCDR, National Cardiovascular Data Registry; NHLBI, National Heart, Lung, and
Blood Institute; PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary angioplasty; QCA, quantitative coronary angiography; SCAI, Society for Cardiac
Angiography and Interventions; SNOMED-CT, Systemized Nomenclature of Medicine–Clinical Terms; TIMI, Thrombolysis in Myocardial Infarction; TLF, target lesion failure; TLR, target
lesion revascularization; TVF, target vessel failure; TVR, target lesion revascularization; and UA, unstable angina.
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supply blood to the
inferior wall of the left
ventricle, classiﬁed










WG, Edwards JE, Frye




















Medina A, Suarez de






Left The PDA and PLA arise
from the left circumﬂex
artery.
Right The PDA and PLA arise
from the right coronary
artery.
Co-dominant The right coronary
artery supplies the PDA,
and the circumﬂex
artery supplies the PLA.
Thus, both the right
coronary and left
circumﬂex arteries
contribute to the blood
supply of the inferior








 Mid right coronary
artery
















 Left main coronary
artery ostium
Revised from Austen
WG, Edwards JE, Frye




















Medina A, Suarez de
Lezo J, Pan M.
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 Left main coronary
artery body
 Left main coronary
artery bifurcation






















 Mid left circumﬂex
artery
 Distal left circum-
ﬂex artery
 First obtuse mar-
ginal branch
 First obtuse mar-
ginal lateral branch
 Second obtuse mar-
ginal branch
 Second obtuse mar-
ginal lateral branch
 Third obtuse mar-
ginal branch























Origin of the right
coronary artery,







Proximal portion of the
right coronary artery,
from the ostium of the
right coronary artery to






Mid right coronary artery Middle portion of the
right coronary artery,
from the origin of the
ﬁrst right ventricular







Continued on the next page
APPENDIX 10. CONTINUED
J A C C V O L . 6 6 , N O . 4 , 2 0 1 5 Hicks et al.














Distal portion of the
right coronary artery,
from the acute margin







Right PDA In right dominant and
mixed circulations, the































































Right ventricular branch Branch arising from the








Origin of the left
coronary artery,






Body of the left main
coronary artery, from







Distal end of the left
main coronary artery,
including the terminal
3 mm through the
bifurcation of the left
main into the LAD and
left circumﬂex arteries
Draft code: 11c
LAD artery ostium Origin of the LAD
coronary artery,
including the ﬁrst 3 mm
of the artery
Draft code: 12a
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Proximal LAD artery Proximal portion of the
LAD coronary artery,
from the ostium to the




Mid LAD artery Middle portion of the
LAD coronary artery,
from the origin of the
ﬁrst septal artery to the





Distal LAD artery Distal portion of the
LAD coronary artery,
from the origin of the





First diagonal branch First of the 3 longest
branches originating
from the LAD artery to
supply the anterolateral










Second diagonal branch Second of the 3 longest
branches originating
from the LAD artery to
supply the anterolateral










Third diagonal branch Third of the 3 longest
branches originating
from the LAD artery to
supply the anterolateral






















Origin of the left
circumﬂex coronary
artery, including the




Proximal portion of the
left circumﬂex coronary
artery, from the ostium
to the origin (or the





Mid left circumﬂex artery Middle portion of the
left circumﬂex coronary
artery, from the origins
of (or nominal locations







Distal portion of the left
circumﬂex coronary
artery, from the origin
of (or the nominal







Continued on the next page
APPENDIX 10. CONTINUED
J A C C V O L . 6 6 , N O . 4 , 2 0 1 5 Hicks et al.












to the origin of the ﬁrst




First of the 3 longest
branches originating
from the left circumﬂex
artery to supply the














Second of the 3 longest
branches originating
from the left circumﬂex
artery to supply the













Third of the 3 longest
branches originating
from the left circumﬂex
artery to supply the




























that arises from the
distal continuation of
the left atrioventricular
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[value set]  Infrarenal aorta
 Left renal artery
 Right renal artery
 Left common iliac
artery
 Right common iliac
artery
 Left external iliac
artery
 Right external iliac
artery
 Left internal iliac
artery






















 Left anterior tibial
artery






 Left peroneal artery
 Right peroneal
artery
 Left posterior tibial
artery
 Right posterior tibial
artery




Diehm N, Pattynama PM,





deﬁnitions. Eur J Vasc
Endovasc Surg.
2008;36:409–19 (60).
Infrarenal aorta Draft code: 400
Left renal artery Draft code: 501
Right renal artery Draft code: 401
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Left external iliac artery Draft code: 503
Right external iliac artery Draft code: 403
Left internal iliac artery Draft code: 504







































Left peroneal artery Draft code: 512













This table describes coronary artery dominance, coronary artery segments, and lower abdominal, pelvic, and lower extremity artery segment concepts. The bulleted lists are the permissible
values for the terminology concept; the following rows provide more detail about the individual permissible values. The table includes a draft simple numbering code for the coronary and
peripheral artery segments, as well as references to existing coding systems describing the speciﬁc segments where available. The numbering code schema uses the letter “a” to designate
the ostium, “b” to designate the body, “c” to designate the bifurcation terminus, and “d” to identify a lateral branch of a branch.
BARI indicates Bypass Angioplasty Revascularization Investigators; LAD, left anterior descending; NCI, National Cancer Institute; PDA, posterior descending artery; PLA, postero-
lateral artery; and SNOMED-CT, Systemized Nomenclature of Medicine–Clinical Terms.
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PVI A PVI is a catheter-based or
open surgical procedure
designed to improve arterial
or venous blood ﬂow or
otherwise modify or revise
vascular conduits.
Procedures may include, but











and open surgical bypass or
revision. In general, the
intention to perform
percutaneous vascular
intervention is denoted by
the insertion of a guidewire
into an artery or vein. For
the sake of simplicity, this
deﬁnition applies to the
extracranial carotid artery
and other noncardiac







PVI—Status Classiﬁcation of the urgency
of a PVI procedure at the












modeled on the similar
coronary PCI concept.
Elective A procedure that is
scheduled and
performed on a patient
with stable disease or in






Urgent A procedure that is not
an emergency but is
required to be
performed on a timely
basis (#24 h) (e.g., a
patient who has been
stabilized following
initial treatment of




should occur within the
next 24 h).
Emergency A procedure that is
required to be
performed immediately
because of the acute
nature of the medical
condition (e.g., acute
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Name of the peripheral
artery segment where PVI
was performed that is the
subject of clinical
investigation. In the context
of clinical investigation, any
lesion treated or for which
treatment was attempted
with a device or technique
being studied. The length of
the target lesion is inclusive
of the section of vessel
treated with the study
device (e.g., a stent) and the
10 mm proximal and 10 mm







PVI—Procedure Success Achievement of a
satisfactory ﬁnal residual
diameter stenosis by
angiography at the end of





parameter for ﬁnal percent
residual stenosis is typically
between <30% and <50%;
selection of the appropriate
percentage may vary






implies absence of in-
hospital major adverse
events (e.g., death, stroke,
MI, acute onset of limb





In the context of clinical
investigation, ideally the
assessment of the residual





The balloon inﬂation, stent
placement, or other
therapeutic intervention





laser, and chronic total
occlusion crossing device),







Adapted from Diehm N,
Pattynama PM, Jaff MR,




deﬁnitions. Eur J Vasc
Endovasc Surg.
2008;36:409–19 (60).
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PVI—Stent Restenosis Renarrowing of a stent
implanted at a lesion site to
treat a prior stenosis, to a
diameter stenosis of >50%
within the stent, inclusive of
the original treated site plus
the adjacent vascular
segments 10 mm proximal









Adapted from Diehm N,
Pattynama PM, Jaff MR,




deﬁnitions. Eur J Vasc
Endovasc Surg.
2008;36:409–19 (60).
PVI—Lesion Restenosis Renarrowing of a lesion site
following treatment of a
prior stenosis, to a diameter
stenosis of >50% at the
previously treated lesion
site, inclusive of the original
treated site plus the
adjacent vascular segments
10 mm proximal and 10 mm









Adapted from Diehm N,
Pattynama PM, Jaff





deﬁnitions. Eur J Vasc
Endovasc Surg.
2008;36:409–19 (60).
PVI—TLR Repeat PVI of a target lesion
(including 10 mm proximal
and 10 mm distal to the
index device) or surgical
intervention/bypass of a
target vessel, performed
for restenosis or other
complication involving
the target lesion.
In the assessment of TLR,
angiograms should be






should be made available to









Adapted from Diehm N,
Pattynama PM, Jaff MR,




deﬁnitions. Eur J Vasc
Endovasc Surg.
2008;36:409–19 (60).
PVI—Ischemia Before TLR Criteria for clinical or
functional ischemia include




b) Critical limb ischemia
c) Recurrence of the clin-












modeled on the similar
coronary PCI concept.
PVI—Clinically Driven TLR TLR is clinically driven if the
target lesion diameter
stenosis is >50% AND the




critical limb ischemia) OR
recurrence of the clinical
syndrome for which the
initial procedure was
performed. Clinically driven













Adapted from Diehm N,
Pattynama PM, Jaff MR,




deﬁnitions. Eur J Vasc
Endovasc Surg.
2008;36:409–19 (60).
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PVI—TLF The composite of ischemia-
driven TLR AND either




critical limb ischemia) OR
recurrence of the clinical
syndrome for which the
initial procedure was
performed. If it cannot be
determined with certainty
whether clinical/functional
ischemia or the clinical
syndrome was related to the







Adapted from Diehm N,
Pattynama PM, Jaff MR,




deﬁnitions. Eur J Vasc
Endovasc Surg.
2008;36:409–19 (60).
PVI—Target Vessel Name of the peripheral
artery level containing a
PVI target lesion that is
the subject of clinical
investigation. In the context
of clinical investigation, a
target vessel is any
noncardiac or
nonintracranial blood vessel
that contains the target
lesion treated with the study
device. The target vessel
includes the target lesion as
well as the entire length of
native vessel upstream and
downstream from the target
lesion, including side
branches.
For the arteries of the leg,
the vasculature is divided









Adapted from Diehm N,
Pattynama PM, Jaff MR,




deﬁnitions. Eur J Vasc
Endovasc Surg.
2008;36:409–19 (60).
Aorto-iliac Infrarenal aorta and iliac
arteries (to the bottom




Femoro-popliteal Femoral and popliteal





Tibial-crural Anterior tibial and
below, including the
arteries of the foot.
PVI—TVR Repeat intervention or
surgical bypass of any
segment of a target vessel.
In the assessment of TVR,
angiograms should be






should be made available to











modeled on the similar
coronary PCI concept.
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PVI—Vessel Patency The absence of clinically
driven TLR and/or absence
of recurrent target lesion





If patency data are
incorporated within the




images should be assessed
by appropriate core
laboratories and made






Adapted from Diehm N,
Pattynama PM, Jaff MR,




deﬁnitions. Eur J Vasc
Endovasc Surg.
2008;36:409–19 (60).
PVI—Target Limb The target limb is the
extremity that contains the
target lesion and all the








Adapted from Diehm N,
Pattynama PM, Jaff MR,




deﬁnitions. Eur J Vasc
Endovasc Surg.
2008;36:409–19 (60).
PVI—Target Limb Failure TLF is the composite of
ischemia-driven
revascularization of the
target limb and major
adverse ischemic events
affecting the target limb. If
it cannot be determined
with certainty whether an
event was related to the







Adapted from Diehm N,
Pattynama PM, Jaff MR,









Name of a peripheral artery
segment where PVI was
performed that is NOT the
subject of clinical
investigation. In the context
of clinical investigation, any
lesion not treated or for
which treatment was not
attempted with the device
or technique being studied.
This includes lesions treated











Any (de novo or repeat)
vascular intervention of a
nontarget lesion or bypass
surgery of a nontarget
vessel. This includes
revascularization at the time
of an index (study) vascular













Adapted from Diehm N,
Pattynama PM, Jaff MR,




deﬁnitions. Eur J Vasc
Endovasc Surg.
2008;36:409–19 (60).
PVI—Nontarget Vessel In the context of clinical
investigation, any vessel or
bypass graft not treated or
for which treatment was not








Adapted from Diehm N,
Pattynama PM, Jaff MR,
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This includes vessels treated
with (nonstudy) vascular
intervention and vessels
managed medically. For the
arteries of the leg, the




deﬁnitions. Eur J Vasc
Endovasc Surg.
2008;36:409–19 (60).
Aorto-iliac Infrarenal aorta and iliac
arteries (to the bottom




Femoro-popliteal Femoral and popliteal





Tibial-crural Anterior tibial and
below, including the
arteries of the foot.
PVI—Nontarget Vessel
Revascularization
Any (de novo or repeat)
vascular intervention or
surgical bypass of any
segment of a nontarget
vessel. This includes
revascularization of a
nontarget lesion at the time
of an index (study) vascular
intervention or subsequent















Location of a lesion within a
peripheral artery bypass













The section of a graft
from the connection
(anastomosis) of the
graft with the proximal
artery, inclusive of the
ﬁrst 3 mm of the graft.
Graft body The section of a graft
between the proximal
and distal anastomoses.
Graft anastomosis—distal The section of a graft
from the connection
(anastomosis) of the
graft with the distal
artery, inclusive of the
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Synthetic graft Bypass graft composed
of nonbiological conduit
material.
Composite graft Bypass graft composed
of a composite of
materials.
Cadaveric graft—arterial Bypass graft composed
of artery harvested
from a cadaver.
Cadaveric graft—venous Bypass graft composed
of vein harvested from a
cadaver.






























Adapted from Diehm N,
Pattynama PM, Jaff MR,




deﬁnitions. Eur J Vasc
Endovasc Surg.
2008;36:409–19 (60).
CEC indicates Clinical Events Committee; PTFE, polytetraﬂuoroethylene; PVI, peripheral vascular intervention; TLF, target lesion failure; TLR, target lesion revascularization; and TVR,
target vessel revascularization.
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